Identifying and treating the early lichenoid stages of cutaneous chronic graft versus host disease
By identifying early lichenoid stages of cGVHD through CSFlR+ macrophage and lysozyme+ macrophage analysis and treating with CSF1R inhibitors, the progression to sclerotic lesions is prevented, enhancing treatment efficacy for HCT patients.
Patent Information
- Application Number
- PCT/US2026/027303
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-10-31
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for chronic graft versus host disease (cGVHD) are ineffective at addressing early lichenoid stages, leading to significant skin and organ damage before sclerotic lesions develop, as they rely on clinical symptoms rather than objective tissue criteria.
Identify early lichenoid stages of cGVHD through determining the proportion of CSFlR+ macrophages and lysozyme+ macrophages and their distance from basal keratinocytes, and treat with a CSF1R inhibitor like axatilimab to prevent progression to sclerotic lesions.
Early intervention in lichenoid stages of cGVHD using CSF1R inhibitors significantly reduces or prevents the development of sclerotic lesions, preserving organ function and improving clinical outcomes for HCT patients.
Smart Images

Figure IMGF000025_0001 
Figure IMGF000025_0002 
Figure IMGF000025_0003
Abstract
Description
20443-0963WO1 / INCY0626-WO1IDENTIFYING AND TREATING THE EARLY LICHENOID STAGES OF CUTANEOUS CHRONIC GRAFT VERSUS HOST DISEASECROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of priority to U.S. Provisional Patent Application No. 63 / 803,184, filed on May 9, 2025, and U.S. Provisional Patent Application No. 63 / 909,477, filed on October 31, 2025, the entire contents of are hereby incorporated by reference in their entirety.STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH
[0002] This invention was made with government support under CA236229, CAI 18953, CA018029, TR002317, and CA015704 awarded by the National Institutes of Health. The government has certain rights in the invention.SEQUENCE LISTING
[0003] This application contains a Sequence Listing that has been submitted electronically as an XML file named 20443-0963W01_SL.xml. The XML file, created on May 5, 2026, is 17,846 bytes in size. The material in the XML file is hereby incorporated by reference in its entirety.FIELD OF THE DISCLOSURE
[0004] The current disclosure describes identifying and treating early lichenoid stages of cutaneous chronic graft versus host disease (cGVHD) before sclerotic symptoms of the condition emerge. Methods for identifying the early lichenoid stages of cutaneous cGVHD include determining the proportion of macrophages expressing colony-stimulating factor 1 receptor (CSFlR)mtand lysozyme (LYZ)hland the distance between the CSFlRintLYZhlmacrophages and a basal keratinocyte layer within a skin sample obtained from a subject, among other methods disclosed herein. Methods for treating early lichenoid stages of cutaneous cGVHD include administering a therapeutically effective amount of a CSF1R inhibitor to the subject.BACKGROUND
[0005] Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for hematological malignancies as well as refractory autoimmune diseases such as systemic20443-0963WO1 / INCY0626-WO1lupus erythematosus (SLE). For subjects with hematological malignancies, HCT allows for administration of higher and more potentially effective dosages of chemotherapy and radiotherapy. For subjects with abnormal nonmalignant lymphohematopoietic systems, HCT allows for replacement of the abnormal lymphohematopoietic system with a healthy one. HCT is often referred to as bone marrow transplantation (BMT).
[0006] Unfortunately, HCT results in allogeneic hematopoietic chimerism, and half of HCT transplant recipients develop graft versus host disease (GVHD). GVHD occurs when transplanted T cells attack and damage a subject’s own cells. GVHD may present as an acute or chronic condition, each with different symptoms. Acute GVHD (aGVHD) causes temporary rash, while chronic GVHD (cGVHD) causes serious damage, including inflammation and scarring of the skin, mouth, eyes, joints, liver, lung, esophagus, and gastrointestinal tract. Fourteen thousand patients in the U.S. are living with cGVHD, and it is one of the leading causes of medical problems and death after HCT.
[0007] The current standard of care for refractory or recurrent cutaneous cGVHD includes administration of the colony-stimulating factor 1 receptor (CSF1R) inhibitor, axatilimab. By the time patients reach this stage of the disorder, significant damage to the skin, mouth, eyes, joints, liver, lung, esophagus, and gastrointestinal tract has likely occurred.SUMMARY
[0008] The current disclosure describes a method of identifying and treating early lichenoid stages of cutaneous chronic graft versus host disease (cGVHD) before sclerotic symptoms emerge, resulting in reduced, delayed, or prevented development of sclerotic lesions.
[0009] The inventors have identified that lichenoid cGVHD can be divided into distinct, biologically-defined patient subgroups. While cGVHD subjects frequently manifest lichenoid features, the presence of lichenoid morphology alone is insufficient to distinguish these subgroups. Instead, they may be identified by objective tissue criteria and not just the clinical stage of disease. One of these subgroups includes a dominant CSFIR-positive macrophage presentation, and is predicted to be therapeutically responsive to CSF1R inhibition. Specifically, a subset of subjects with cGVHD is characterized by macrophage-driven inflammation localized to the epidermal -dermal interface. This patient subgroup exhibits a pathogenic triad involving CSF1R macrophages, CD8 T cells, and basal keratinocytes, leading to aberrant epithelial activation, fibroblast reprogramming, and progression towards fibrosis.20443-0963WO1 / INCY0626-WO1
[0010] Methods for identifying the early lichenoid stages of cutaneous cGVHD include determining the proportion of macrophages expressing colony-stimulating factor 1 receptor (CSFlR)mtand lysozyme (LYZ)hland the distance between the CSFlRintLYZhlmacrophages and a basal keratinocyte layer within a skin sample obtained from a subject, among other methods disclosed herein. In particular embodiments, if the amount of CSFlRintLYZhlmacrophages is increased in the skin sample compared to a reference level derived from a subject who does not have cGVHD, then the sample identifies the lichenoid stage of cGVHD. In particular embodiments, if the CSFlRintLYZhlmacrophages are closer to the basal keratinocyte layer in the skin sample compared to a reference level derived from a subject who does not have cGVHD, then the sample identifies the lichenoid stage of cGVHD. In particular embodiments, if the skin sample is in the lichenoid stage of cutaneous cGVHD, early intervention in the disease process can be initiated. In particular embodiments, early intervention includes administering a therapeutically effective amount of a CSF1R inhibitor. In particular embodiments, the CSF1R inhibitor includes axatilimab. In particular embodiments, the subject is treated before the later- sclerotic stages of cutaneous cGVHD develop, resulting in significantly improved clinical outcomes for HCT patients.BRIEF DESCRIPTION OF THE FIGURES
[0011] FIG. 1. Characteristics of patients included in lichenoid chronic graft-versus-host disease (cGVHD) analyses. Abbreviations: M (male); F (female); ALL (acute lymphoid leukemia); AML (acute myeloid leukemia); MDS (myelodysplastic syndromes); PNH (paroxysmal nocturnal hemoglobinuria); MP AL (mixed phenotype acute leukemia); CLL (chronic lymphocytic leukemia); PBSC (peripheral blood stem cells); MUD (matched unrelated donor); MRD (matched related donor); TBI (total body irradiation); MTX (methotrexate); MMF (my cophenolate mofetil); CSP (cyclosporine); R (right); L (left); GI (gastrointestinal).
[0012] FIG. 2. Xenium gene probe panel used in lichenoid cGVHD analyses.
[0013] FIGs. 3A-3B. cGVHD skin segregates by degree of immune cell infiltration. (3 A) Numbers of macrophages / dendritic cells (DCs) and T cells normalized to each sample’s number of basal keratinocytes. (3B) Proportions of cell types within each sample.
[0014] FIGs. 4A-4G. Highly immune cell-infiltrated cGVHD skin is distinguished by presence of CSFlRmtLYZhlmacrophages associating closely with CD8 T cells and basal keratinocytes. (4A) Proportions of cell types within each sample. (4B) Numbers of20443-0963WO1 / INCY0626-WO1macrophages and DCs normalized to the number of basal keratinocytes. (4C) Physical proximity of myeloid cell types to basal keratinocytes, by sample. (4D) Pseudobulked differentially expressed genes in skin macrophages from HI and Control groups. (4E) Numbers of T cells normalized to basal keratinocyte number in each sample. (4F) Physical proximity of T cell types to basal keratinocytes, by sample. (4G) “Round trip” proximity between each T cell and macrophage subset.
[0015] FIG. 5. Macrophage cluster marker genes. Markers identified on object containing macrophage clusters only (without DC clusters) via Seurat Find AllMarkers function with cutoff p_val_adj<0.05.
[0016] FIG. 6. Lineage-related T cell gene expression in lichenoid skin cGVHD. Number of TBX21-, IFNG-, RORC-, and IL17A-expressing T cells normalized for numbers of basal keratinocytes. (
[0017] FIGs. 7A-7D. Lichenoid cGVHD is associated with changes in collagen-producing reticular and papillary fibroblasts. (7 A) Proportions of cell types within each sample. (7B) Numbers of fibroblasts normalized to basal keratinocytes in each sample. (7C) Proximity of fibroblast types to basal keratinocytes, by sample. (7D) Pseudobulked differentially expressed genes in major fibroblast populations of HI versus Control groups.
[0018] FIGs. 8A, 8B. Fibroblast gene expression. (8A) Fibroblast cluster marker genes, obtained via Seurat Find AllMarkers function, with cutoffs of pct.l>0.2, avg_log2FC>0.5, and p_val_adj<0.05. (8B) Total fibroblast pseudobulked DEGs (HI vs. Control), obtained via DESeq2, using thresholds of baseMean>100 and padj<0.05.
[0019] FIGs. 9A-9F. Highly immune cell-infiltrated cGVHD skin results in dysregulated keratinocyte development associated with injury and immune modulation. (9 A) Proportions of cell types within each sample. (9B) Marker genes of each keratinocyte cluster (from left to right: granular keratinocyte markers; abnormal spinous keratinocyte markers; normal spinous keratinocyte markers; abnormal basal keratinocyte markers; and normal basal keratinocyte markers and from top to bottom: basal keratinocytes; abnormal basal keratinocytes; spinous keratinocytes; abnormal spinous keratinocytes; and granular keratinocytes. (9C) Pseudobulked differentially expressed genes in keratinocyte populations of HI versus Control groups. (9D) T cell and macrophage proximity to basal keratinocytes as a linear function of basal keratinocyte gene expression, with High Infiltration and Control samples aggregated, respectively. Filtered for absolute Spearman correlation coefficient >0.15 and gene expression in basal keratinocytes greater than that of adjacent cells. (9E) Approach to calculating difference in immune cell proximity according to gene-positive basal20443-0963WO1 / INCY0626-WO1keratinocytes vs. gene-negative basal keratinocytes. In HI samples, immune cells were closer to gene-positive basal keratinocytes compared to gene-negative basal keratinocytes. (9F) Immune cell proximities to basal keratinocytes based on presence vs. absence of GJB2, CXCL14, and CD74 expression. When gene expression was dichotomized as expressed vs. non-expressed, basal keratinocytes expressing GJB2 in HI samples correlated with closer proximity to CD8 T cells (the highest magnitude of impact) plus Tregs and CD4 T cells, as well as closer T cell subsets expressing TBX21, RORC, IFNG, and IL17A . CXCL14-expressing basal keratinocytes were closer to RORC+ and CD4+ expressing T cells and Tregs in HI samples. CXCL14-expressing basal keratinocytes were farther from NKT cells in HI samples. CD74-expressing basal keratinocytes were closer to TBX21+ and IFNG+ expressing T cells, NKT cells, and CSFlRintLYXhlmacrophages in HI samples. Immune cell clusters are as defined in FIGs. 4A-4G.
[0020] FIG. 10. Characteristics of AGAVE-201 patients included in pre- and post-axatilimab analyses. Abbreviations: PR (partial response); CR (complete response); ORR (overall response rate); C2D1 (cycle 2 day 1); C6D1 (cycle 6 dayl); and C7D1 (cycle 7 day 1).
[0021] FIG. 11. Xenium gene probe panel used in AGAVE-201 pre- and post-axatilimab analyses.DETAILED DESCRIPTION
[0022] Allogeneic hematopoietic cell transplantation (HCT) is a curative therapy for hematological malignancies as well as refractory autoimmune diseases such as systemic lupus erythematosus (SLE). For subjects with hematological malignancies, HCT allows for administration of higher and more potentially effective dosages of chemotherapy and radiotherapy. For subjects with abnormal nonmalignant lymphohematopoietic systems, HCT allows for replacement of the abnormal lymphohematopoietic system with a healthy one. HCT is often referred to as bone marrow transplantation (BMT).
[0023] HCT results in allogeneic hematopoietic chimerism. Thus, unfortunately, half of HCT transplant recipients develop graft versus host disease (GVHD), which occurs when transplanted T cells attack and damage a subject’s own cells. GVHD may present as an acute or chronic condition, each with different symptoms. Acute GVHD (aGVHD) causes temporary rash, while chronic GVHD (cGVHD) causes serious damage, including inflammation and scarring of the skin, mouth, eyes, joints, liver, lung, esophagus, and gastrointestinal tract. Fourteen thousand patients in the U.S. are living with cGVHD, and it is20443-0963WO1 / INCY0626-WO1one of the leading causes of medical problems and death after HCT.
[0024] Cutaneous cGVHD can involve nonsclerotic “lichenoid” skin lesions and sclerotic skin lesions. Lichenoid lesions are commonly thought to precede the development of sclerotic lesions during the course of cGVHD progression. Lichenoid skin lesions are generally caused by an bandlike infiltration of inflammatory cells into the superficial dermis, parallel to the epidermis. The clinical features of lichenoid lesions can vary depending on the type and degree of inflammatory cell infiltration. These lesions most often present small, solitary, brown macules or papules that can turn red and itchy. Their texture can be smooth, scaly, or warty. In HCT patients, lichenoid lesions often include lichen planus. Lichen planus is a chronic, inflammatory skin condition that often affects mucous membranes, such as those inside the mouth. Lichen planus is characterized by an itchy rash with small, purple-colored papules that can also appear as lacy white patches or sores.
[0025] As noted, lichenoid skin lesions can precede the development of cutaneous sclerotic skin lesions. Sclerotic skin lesions have excessive local accumulation of collagen and / or other extracellular matrix components in the dermis, subcutaneous tissue, and / or underlying soft tissues resulting in a hardening and tightening of the skin. Sclerotic lesions are characterized by patches of thick, hard skin, often with a waxy or yellow appearance and a reddish or bruise-like border. Such lesions can result in significant skin and organ damage, particularly to the mouth, eyes, joints, liver, lung, esophagus, and gastrointestinal tract.
[0026] Active cGVHD can be defined as the presence of signs and symptoms of cGVHD per the 2014 National Institutes of Health (NIH) Consensus Development Project on Criteria for Clinical trials in cGVHD. According to these guidelines, active or acute cGVHD of the skin can be identified by apoptosis in the epidermal basal layer or lower Malphigian layer. Lichen planus-like skin is characterized by a combination of epidermal orthohyperkeratosis, hypergranulosis and acanthosis resembling lichenplanus and / or lichenoid inflammation and / or vacuolar changes of eccrine units. Morphetic skin is characterized by the thickening and homogenization of collagen bundles throughout the reticular dermis or pandermal sclerosis with overlying interface changes. It is also common to see thickening and homogenization of subcutaneous septa. Lichen sclerosus-like skin is identified by homogenization and sclerosis of papillary dermal collagen with overlying interface changes including melanophages in the papillary dermis and sparse lymphocytic infiltrate. Fascitis includes thickening of fascial septa with adjacent inflammation and possible sclerosis of the subcutis.
[0027] The current disclosure describes methods to identify and treat the early20443-0963WO1 / INCY0626-WO1lichenoid stages of cutaneous cGVHD to reduce, delay, or prevent the more serious occurrence of sclerotic skin lesions. Reducing, delaying, or preventing the development of sclerotic skin lesions can preserve organ function in HCT patients. In particular embodiments, function of the skin, mouth, eyes, joints, liver, lung, esophagus, and gastrointestinal tract are preserved.
[0028] In particular embodmients, methods for identifying the early lichenoid stages of cutaneous cGVHD include determining the proportion of macrophages expressing colonystimulating factor 1 receptor (CSFlR)mtand lysozyme (LYZ)hland the distance between the CSFlRintLYZhlmacrophages and a basal keratinocyte layer within a skin sample obtained from a subject. In particular embodiments, if the amount of CSFlRintLYZhlmacrophages is increased in the skin sample compared to a reference level derived from a subject that does not have cGVHD, then the sample is in the lichenoid stage of cGVHD. In particular embodiments, if the CSFlRintLYZhlmacrophages are closer to the basal keratinocyte layer in the skin sample compared to a reference level derived from a subject that does not have cGVHD, the sample is in the lichenoid stage of cGVHD. In particular embodiments, if the skin sample is in the lichenoid stage of cutaneous cGVHD, then treatment can be initiated before lesion development progresses, for example, before the late- sclerotic stages of cutaneous cGVHD. In particular embodiments, methods for treating early lichenoid stages of cutaneous cGVHD can include administering a therapeutically effective amount of a CSF1R inhibitor. In particular embodiments, the CSF1R inhibitor includes axatilimab.
[0029] Aspects of the current disclosure are now described in more supporting detail as follows: (i) Skin Sample Acquisition and Treatment; (ii) Detection and Quantification of Biomarkers; (iii) Reference Levels; (iv) CSF-R Inhibitors; (v) Compositions; (vi) Methods of Treatment; (vii) Exemplary Embodiments; (viii) Experimental Examples; and (ix) Closing Paragraphs. These headings are provided for organizational purposes only and do not limit the scope or interpretation of the disclosure.
[0030] (i) Skin Sample Acquisition and Treatment. A skin sample from a subject can be used to determine if a subject has cutaneous cGVHD (e.g., at the lichenoid stage of cGVHD). The skin sample may be obtained from a subject using methods well known to the skilled person in the art. For example, the skin sample may be obtained bya skin punch biopsy, excisional biopsy, incisional biopsy, saucerization biopsy, fine-needle aspiration biopsy, scraped cells, skin shave biopsies, skin stripping (e.g. using adhesive tape), or using the suction blister method. An “excisional biopsy” refers to the removal of an entire lesion or malformation with a small margin of normal tissue surrounding it. An20443-0963WO1 / INCY0626-WO1“incisional biopsy” refers to the removal of a wedge of tissue that includes a cross-sectional diameter of the lesion or malformation. Molecular profiling can use a “core-needle biopsy” of the lesion or malformation mass, or a “fine-needle aspiration biopsy” which generally obtains a suspension of cells from within the lesion or malformation. Biopsy techniques are discussed, for example, in Harrison's Principles of Internal Medicine, Kasper, et al., eds., 16th ed., 2005, Chapter 70, and throughout Part V.
[0031] The samples can be collected from subjects repeatedly over a longitudinal period of time (e.g., once or more on the order of days, weeks, months, annually, biannually, etc.). Obtaining numerous samples from a subject over a period of time can be used to verify results from earlier detections and / or to identify an alteration in biological pattern as a result of, for example, disease progression, drug treatment, etc. For example, subject samples can be taken and monitored every month, every two months, or combinations of one, two, or three month intervals according to the present invention. In addition, the biomarker amount and / or proximity measurements of the subject obtained over time can be conveniently compared with each other, as well as with those of normal controls during the monitoring period, thereby providing the subject's own values, as an internal, or personal, control for long-term monitoring.
[0032] A variety of steps can be performed to prepare a biological sample for analysis. Preparative steps described below can be performed alone or in combination in any manner to appropriately prepare a particular sample for analysis.
[0033] Tissue Sectioning. A biological sample can be harvested from a subject or grown in vitro on a growth substrate or culture dish as a population of cells, arid prepared for analysis as a tissue slice or tissue section. Grown samples may be sufficiently thin for analysis without further processing steps. Alternatively, grown samples,and samples obtained via biopsy or sectioning, can be prepared as thin tissue sections using a mechanical cutting apparatus such as a vibrating blade microtome. As another alternative, in some embodiments, a thin tissue section can be prepared by applying a touch imprint of a biological sample to a suitable substrate material.
[0034] The thickness of the tissue section can be a fraction of (e.g., less than 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, or 0.1) the maximum cross-sectional dimension of a cell.However, tissue sections having a thickness that is larger than the maximum cross-section cell dimension can also be used. For example, cryostat sections can be used, which can be, e.g., 10-20 micrometers thick.
[0035] More generally, the thickness of a tissue section typically depends on the20443-0963WO1 / INCY0626-WO1method used to prepare the section and the physical characteristics of the tissue, and therefore sections having a wide variety of different thicknesses can be prepared and used. For example, the thickness of the tissue section can be at least 0.1, 0.2, 0.3, 0.4, 0.5, 0.7, 1.0, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 30, 40, or 50 micrometers. Thicker sections can also be used if desired or convenient, e.g., at least 70, 80, 90, or 100 micrometers or more. Typically, the thickness of a tissue section is between 1-100 micrometers, 1-50 micrometers, 1-30 micrometers, 1-25 micrometers, 1-20 micrometers, 1-15 micrometers, 1-10 micrometers, 2-8 micrometers, 3-7 micrometers, or 4-6 micrometers, but as mentioned above, sections with thicknesses larger or smaller than these ranges can also be analyzed.
[0036] Multiple sections can also be obtained from a single biological sample. For example, multiple tissue sections can be obtained from a surgical biopsy sample by performing serial sectioning of the biopsy sample using a sectioning blade. Spatial information among the serial sections can be preserved in this manner, and the sections can be analyzed successively to obtain three-dimensional information about thebiological sample.
[0037] Freezing. In some embodiments, the biological sample (e.g., a tissue section as described above) can be prepared by deep freezing at a temperature suitable to maintain or preserve the integrity (e.g., the physical characteristics) of the tissue structure. Such a temperature can be, e.g., less than -20° C., or less than -25° C., -30° C., -40° C., -50° C., -60° C., -70° C., -80° C., -90° C., -100° C., -110° C., -120° C., -130° C., -140° C., -150° C., -160° C., -170° C., -180° C., -190° C., or -200° C. The frozen tissue sample can be sectioned, e.g., thinly sliced, onto a substrate surface using any number of suitable methods. For example, a tissue sample can be prepared using a chilled microtome (e.g., a cryostat) set at a temperature suitable to maintain both the structural integrity ofthe tissue sample and the chemical properties of the nucleic acids in the sample. Such a temperature can be, e.g., less than -15° C., less than -20° C., or less than -25° C.A sample can be snap frozen in isopentane and liquid nitrogen. Frozen samples can be stored in a sealed container prior to embedding.
[0038] In some embodiments, the skin sample can be prepared using formalin-fixation and paraffin-embedding (FFPE), which are established methods. Following fixation of the sample and embedding in a paraffin or resin block, the sample can be sectioned as described above. Prior to analysis, the paraffin-embedding material can be removed from the tissue section (e.g., deparaffinization) by incubating the tissue section in an appropriate solvent (e.g., xylene) followed by a rinse (e.g., 99.5% ethanol for 2 minutes, 96% ethanol for20443-0963WO1 / INCY0626-WO12 minutes, and 70% ethanol for 2 minutes).
[0039] As an alternative to formalin fixation described above, a biological sample can be fixed in any of a variety of other fixatives to preserve the biological structure of the sample prior to analysis. For example, a sample can be fixed via immersion in ethanol, methanol, acetone, formaldehyde (e.g., 2% formaldehyde), paraformaldehyde-Triton, glutaraldehyde, or combinations thereof.
[0040] In some embodiments, acetone fixation is used with fresh frozen samples. In some embodiments, a compatible fixation method is chosen and / or optimized based on a desired workflow. For example, formaldehyde fixation may be chosen as compatible for workflows using immunohistochemistry or immunofluorescence protocols for protein visualization. As another example, methanol fixation may be chosen for workflows emphasizing RNA / DNA library quality. Acetone fixation may be chosen in some applications to permeabilize the tissue. When acetone fixation is performed, pre-permeabilization steps (described below) may not be performed.Alternatively, acetone fixation can be performed in conjunction with permeabilization steps.
[0041] As an alternative to paraffin embedding described above, abiological sample can be embedded in any of a variety of other embedding materials to provide a substrate to the sample prior to sectioning and other handling steps. In general, the embedding material is removed prior to analysis of tissue sections obtained from the sample. Suitable embedding materials include waxes, resins (e.g., methacrylate resins), epoxies, and agar.
[0042] To facilitate visualization, biological samples can be stained using a wide variety of stains and staining techniques. In some embodiments, for example, a sample can be stained using any number of biological stains such as acridine orange, Bismarck brown, carmine, coomassie blue, cresyl violet, DAPI, eosin, ethidium bromide, acid fuchsine, hematoxylin, Hoechst stains, iodine, methyl green, methylene blue, neutral red, Nile blue, Nile red, osmium tetroxide, propidium iodide, rhodamine, or safranin.
[0043] The sample can be stained using known staining techniques, including Can-Grunwald, Giemsa, hematoxylin and eosin (H&E), Jenner's, Leishman, Masson's trichrome, Papanicolaou, Romanowsky, silver, Sudan, Wright's, and / or Periodic Acid Schiff (PAS) staining techniques. PAS staining is typically performed after formalin or acetone fixation.
[0044] In some embodiments, the sample is stained using a detectable label (e.g., radioisotopes, fluorophores, chemiluminescent compounds, bioluminescent compounds, and dyes) as described elsewhere herein. In some embodiments, a biological sample is stained20443-0963WO1 / INCY0626-WO1using only one type of stain or one technique. In some embodiments, staining includes biological staining techniques such as H&E staining. In some embodiments, staining includes identifying analytes using fluorescently-conjugated antibodies. In some embodiments, a biological sample is stained using two or more different types of stains, or two or more different staining techniques. For example, a biological sample can be prepared by staining and imaging using one technique (e.g., H&E staining and / or brightfield imaging), followed by staining and imaging using another technique (e.g., immunohistochemistry / immunofluorescence staining and fluorescence microscopy) for the same biological sample.
[0045] In some embodiments, biological samples can be destained. Methods of destaining or discoloring a biological sample are known in the art, and generally depend on the nature of the stain(s) applied to the sample. For example, H&E staining can be destained by washing the sample in HC1, or any other low pH acid (e.g., selenic acid, sulfuric acid, hydroiodic acid, benzoic acid, carbonic acid, malic acid, phosphoric acid, oxalic acid, succinic acid, salicylic acid, tartaric acid, sulfurous acid, trichloroacetic acid, hydrobromic acid, hydrochloric acid, nitric acid, orthophosphoric acid, arsenic acid, selenous acid, chromic acid, citric acid, hydrofluoric acid, nitrous acid, isocyanic acid, formic acid, hydrogen selenide, molybdic acid, lactic acid, acetic acid, carbonic acid, hydrogen sulfide, or combinations thereof). In some embodiments, destaining can include 1, 2, 3, 4, 5, or more washes in a low pH acid (e.g., HC1). In some embodiments, destaining can include adding HC1 to a downstream solution (e.g., permeabilization solution). In some embodiments, destaining can include dissolving an enzyme used in the disclosed methods (e.g., pepsin) in a low pH acid (e.g., HC1) solution. In some embodiments, after destaining hematoxylin with a low pH acid, other reagents can be added to the destaining solution to raise the pH for use in other applications. For example, SDS can be added to a low pH acid destaining solution in order to raise the pH as compared to the low pH acid destaining solution alone. As another example, in some embodiments, one or more immunofluorescence stains are applied to the sample via antibody coupling. Such stains can be removed using techniques such as cleavage of disulfide linkages via treatment with a reducing agent and detergent washing, chaotropic salt treatment, treatment with antigen retrieval solution, and treatment with an acidic glycine buffer. Methods for multiplexed staining and destaining are described, for example, in Bolognesi et al., 2017, J. Histochem. Cytochem. 65(8): 431-444, Lin et al., 2015, Nat Commun. 6:8390, Pirici et al., 2009, J. Histochem. Cytochem. 57:567-75, and Glass et al., 2009, J. Histochem. Cytochem. 57:899-905, the entire contents of each of which are20443-0963WO1 / INCY0626-WO1incorporated herein by reference.
[0046] (ii) Detection and Quantification of Biomarkers. Detecting and determining are used interchangeably herein, and each can include various methodologies through which information about a sample or subject is obtained, generated, derived, inferred, or confirmed. Detecting or determining encompasses any technique that yields information, including direct observation or measurement, computation from intermediate measurements, or acquisition of results from an external provider. Detecting or determining can be performed directly or indirectly; prospectively, in real time, or retrospectively (including from archived data); and by human observation (such as by physical examination), automated instrumentation, or any combination thereof. Operations to detect or determine information include observing, measuring, imaging, acquiring or receiving signals, computing values or relationships among values, classifying, segmenting, thresholding, normalizing, scoring, or otherwise processing raw or pre-processed data to yield an outcome such as a diagnosis, presence / absence call, a quantitative value, a categorical label, or a spatial metric. Results may be produced locally by a device, remotely by a server, or obtained from a third-party laboratory, clearinghouse, or data service.
[0047] As used herein, detecting or determining encompasses any modality suitable for interrogating biological or non-biological features of an individual or specimen.Representative modalities include human observation (such as by physical examination), optical (including brightfield, fluorescence, confocal, multiphoton, light-sheet, and optical coherence tomography (OCT)), electron- or ion-based (including scanning electron microscopy (SEM), transmission electron microscopy (TEM), and secondary ion mass spectrometry (SIMS)), acoustic or mechanical (including ultrasound and atomic force microscopy (AFM)), electrical (including impedance spectroscopy, capacitance, amperometry, electrochemical biosensors), magnetic (including NMR / MRI), and spectrometric techniques (including mass spectrometry, Raman, infrared (IR) spectroscopy). Label-based (e.g., antibodies, nucleic acid probes, enzymatic reporters) and label-free techniques (e.g., phase contrast, quantitative phase imaging, surface plasmon resonance) may also be utilized for detecting or determining information. Molecular assays include flow cytometry / CyTOF, immunohistochemistry or immunofluorescence, ELISA, Western blotting, qPCR / ddPCR, RNA-seq (including bulk and single-cell), ATAC-seq, spatial transcriptomics, and in situ hybridization (e.g., RNAscope), as well as microfluidic techniques and lab-on-chip platforms, single-molecule readouts, and combination panels thereof for detecting or determining information.20443-0963WO1 / INCY0626-WO1
[0048] In some embodiments, detecting or determining is computer-implemented. Such computer-implemented detecting or determining can comprise a device or system that receives electrical, optical, or other signals from an instrument; converts the signals to digital form; and executes instructions to denoise, register, segment, gate, cluster, or otherwise convert and / or analyze the converted signals. Computer-implemented detecting or determining devices or systems of the present disclosure can comprise algorithms (such as rule-based, statistical, or machine-learned) configured to compute intensities, expression levels, co-localization, cell phenotypes, distances, densities, gradients, or trajectories. Such devices or systems may output a scalar, vector, matrix, mask, overlay, call set, or report and can apply fixed or adaptive thresholds, confidence intervals, or quality metrics. Results may be generated on-instrument, on an attached processor, or by transmitting data to a remote computing service; in each case, the outcome is detected or determined as described herein. Electrical signal-based detection includes, by way of example, acquiring time-series or frequency-domain outputs from sensors (e.g., photodiodes, CMOS detectors, electrodes), performing filtering, Fourier or wavelet transforms, feature extraction, and classification to determine the presence, level, or spatial relationship of a target.
[0049] As used herein, detecting or determining also includes visual inspection of individuals or samples by a trained or experienced operator (e.g., reviewing stained tissue sections or live-cell images), semi -automated review with software-assisted annotations, fully automated analysis (e.g., script-based pipelines that batch-process images or cytometry files), and outsourcing to a third-party laboratory or analytics provider that returns raw data, processed data, or calls. Physical analyses of samples may be performed on fresh, frozen, or fixed material (e.g., formalin-fixed paraffin-embedded (FFPE) material); in vitro, ex vivo, or in situ; and can use whole tissue, tissue sections, dissociated cells, or microtissues.
[0050] For example, detecting a macrophage subpopulation (e.g., cells characterized as CSFlRintLYZhl) can involve any of the foregoing modalities, such as multiplex immunostaining with image analysis, flow or mass cytometry with gating or clustering, or transcriptomic methods (including spatial transcriptomics) that infer phenotype from marker expression. Additional markers may be detected using any of the foregoing modalities, as disclosed herein, including markers to identify other cell populations such as CD8+ T cells, basal keratinocytes, keratinocyte state markers, papillary fibroblasts, regulatory T cells, and any combinations thereof suitable for resolving cell phenotypes. Any of these modalities constitute “detecting” or “determining,” including detecting or determining the macrophage subpopulation. Similarly, determining a distance or spatial metric (e.g., the distance between20443-0963WO1 / INCY0626-WO1CSFlRintLYZhlmacrophages and a basal keratinocyte layer in a skin specimen) can include segmenting the basal layer and macrophage objects in image data (such as by morphological criteria and / or markers), assigning coordinates, and computing one or more distances (e.g., nearest-neighbor, centroid-to-boundary, path-length along tissue axes), optionally aggregated per field of view, region of interest, or subject. In some embodiments, a proximity score parameter is computed to reflect spatial co-localizations among CSFlRintLYZhlmacrophages, CD8+ T cells, and basal keratinocytes, and the score is compared to a parameter derived from a reference sample to classify tissue state.
[0051] Biomarkers are any measurable substance, cell, protein, or nucleic acid in an organism whose presence, quantity, or location is indicative of a phenomenon. In particular embodiments, a biomarker includes a cell type. In particular embodiments, a biomarker includes the distance between cell types. In particular embodiments, the biomarker includes the amount of CSFlRintLYZhlmacrophages. In particular embodiments, the biomarker includes the distance between CSFlRintLYZhlmacrophages and a basal keratinocyte layer. In particular embodiments, the biomarker indicates that a subject is in the lichenoid stage of cGVHD. In particular embodiments, if the amount of CSFlRintLYZhlmacrophages is increased in a sample compared to a reference level derived from a subject that does not have cGVHD, then the sample is in the lichenoid stage of cGVHD. In particular embodiments, if the CSFlRintLYZhlmacrophages are closer to the basal keratinocyte layer in a sample compared to a reference level derived from a subject that does not have cGVHD, the sample is in the lichenoid stage of cGVHD.
[0052] FIG. 9E depicts the concept of cell proximity. In particular embodiments, proximity between cell types can be measured by building a spatial neighborhood graph using Delaunay triangulation and then computing the expected number of steps in a random walk before a cell of the target type is encountered. In Markov chain analysis this is referred to as the expected absorption time and can be computed efficiently by solving a spare linear system. The proximity measure can also be normalized to account for the local cell type composition by dividing by the expected absorption time after an initial k step preliminary random walk (set to k=100 in practice), which can be thought of as a local shuffle of the cell positions to get a background distribution to which to compare.
[0053] In particular embodiments, a biomarker includes the quantity or proximity of CCL8 macrophages, CD8 T cells, natural killer T (NKT) cells, CSFlRintLYZhlmacrophages, and / or basal keratinocytes. In particular embodiments, a skin sample from a subject with high infiltration (HI) cutaneous cGVHD has more CD8 T cells compared to a sample derived from20443-0963WO1 / INCY0626-WO1a subject without HI cutaneous cGVHD. In particular embodiments, a skin sample from a subject with HI cutaneous cGVHD has CD8 T cells that are the closer lymphoid cell to the BK layer compared to a sample derived from a subject without HI cutaneous cGVHD. In particular embodiments, a skin sample from a subject with HI cell infiltrated cutaneous cGVHD has increased levels of CCL8 macrophages compared to a sample derived from a subject without HI cutaneous cGVHD. In particular embodiments, a skin sample from a subject with HI cutaneous cGVHD has CCL8 macrophages in closer proximity to the BK layer compared to a sample derived from a subject without HI cutaneous cGVHD. In particular embodiments, the macrophages have increased expression of FTH1 and / or CTSB compared to a sample derived from a subject without HI cutaneous cGVHD.
[0054] In particular embodiments, a skin sample from a subject with HI cutaneous cGVHD has more natural killer T (NKT) cells compared to a sample derived from a subject without HI cutaneous cGVHD. In particular embodiments, a skin sample from a subject with HI cutaneous cGVHD has CSFlRintLYZhlmacrophages that are closer to T cells compared to a sample derived from a subject without HI cutaneous cGVHD. In particular embodiments, a skin sample from a subject with HI cutaneous cGVHD has CSFlRintLYZhlmacrophages that are closer to CD8 T cells compared to a sample derived from a subject without HI cutaneous cGVHD. In particular embodiments, a skin sample from a subject with HI cutaneous cGVHD has CD74hlfibroblasts that are closer to the BK layer compared to a sample derived from a subject without HI cutaneous cGVHD.
[0055] In particular embodiments, the biomarker includes gene expression by a select cell type. In particular embodiments, the expression of CD74 and / or CD68 in fibroblasts is higher compared to a sample derived from a subject without HI cutaneous cGVHD. In particular embodiments, the basal keratinocytes have increased expression of CD74, GJB2, KRT6B, ZEB2, and / or TGFB1 compared to a sample derived from a subject without HI cutaneous cGVHD. In particular embodiments, the spinous keratinocytes have increased expression of CD74, GJB2, KRT6B, ZEB2, and / or TGFB1 compared to a sample derived from a subject without HI cutaneous cGVHD. In particular embodiments, the spinous keratinocytes have decreased expression of CDH1 and / or CD9 compared to a sample derived from a subject without HI cutaneous cGVHD.
[0056] In particular embodiments, a biomarker includes expression of collagen genes, SPARC, and / or SFRP2 in LGR5+ fibroblasts. In particular embodiments, subjects will respond to a CSF1R inhibitor if the expression level of collagen genes, SPARC, and / or SFRP2 are decreased compared to the reference level, wherein a reference level is derived20443-0963WO1 / INCY0626-WO1from a non-responder (i.e., a subject or subjects that do not respond to CSF1R inhibitor treatment). In particular embodiments, a biomarker includes expression of POSTN in papillary fibroblasts. In particular embodiments, subject will respond to CSF1R inhibitor if the expression level of POSTN is decreased compared to a reference level, wherein the reference level is derived from a non-responder. In particular embodiments, a biomarker includes expression of ADH1B in papillary fibroblasts. In particular embodiments, subject will respond to CSF1R inhibitor if the expression level of ADH1B is increased compared to a reference level, wherein the reference level is derived from a non-responder. Alternatively, if the gene expression is similar to a reference level, wherein the reference level is derived from a responder (i.e., responder to CSF1R inhibitor), then the subject is predicted to respond to CSF1R inhibitor treatment.
[0057] In particular embodiments, basal keratinocytes expressing GJB2 in HI samples are closer in proximity to CD8 T cells (the highest magnitude of impact) plus Tregs and CD4 T cells, as well as closer T cell subsets expressing TBX21, RORC, IFNG, and IL17A compared to non -HI samples. In particular embodiments, CXCL14-expressing basal keratinocytes are closer to RORC+ and CD4+ expressing T cells and Tregs in HI samples compared to non -HI samples. In particular embodiments, CXCL14-expressing basal keratinocytes are farther from NKT cells in HI samples compared to non-HI samples. In particular embodiments, CD74-expressing basal keratinocytes are closer to TBX21+ and IFNG+ expressing T cells, NKT cells, and CSFlRintLYXhlmacrophages in HI samples compared to non-HI samples.
[0058] In particular embodiments, CSFlRintLYZhlmacrophages are identified by the expression of CSFIRand lysozyme (LYZ). In particular embodiments, cells and cell layers can be identified by structure. For example, the basal keratinocyte layer is the deepest layer of the epidermis, the outermost layer of skin. It is identifiable by its location at the base of the epidermis, directly adjacent to the dermis, and by the presence of mitotically active stem cells that continuously produce keratinocytes. In particular embodiments, macrophages are characterized by their large size and amoeboid shape, which allows them to engulf and engulf pathogens and cellular debris.
[0059] Alternatively, cell types can be distinguished by the markers they express.
[0060] Macrophages (and their precursors, monocytes) reside in every tissue of the body (in certain instances as microglia, Kupffer cells and osteoclasts) where they engulf apoptotic cells, pathogens and other non-self-components. Monocytes / macrophages express CD 11b, F4 / 80; CD68; CD 11c; IL-4Ra; and / or CD 163.20443-0963WO1 / INCY0626-WO1
[0061] Several different subsets of T-cells have been discovered, each with a distinct function. For example, a majority of T-cells have a T-cell receptor (TCR) existing as a complex of several proteins. The actual T-cell receptor is composed of two separate peptide chains, which are produced from the independent T-cell receptor alpha and beta (TCRa and TCRP) genes and are called a- and P-TCR chains.
[0062] Keratinocytes, the main cell type of the epidermis, can be identified by various markers, including keratins, involucrin, and other proteins involved in cell differentiation and barrier formation.
[0063] Fibroblasts, known for their role in tissue repair and extracellular matrix production, can be identified using a combination of markers, including mesenchymal markers like vimentin and PDGFRa. Other commonly used markers include a-smooth muscle actin (a-SMA), CD90, FSP1, and FAP, particularly in activated fibroblasts.
[0064] Up- or down-regulation of the biomarkers, as indicated elsewhere herein for particular biomarkers, can be assessed by comparing a measured value (from a test or subject sample) to a relevant reference level. For example, the quantity of one or more biomarkers can be indicated as a value. The value can be expressed numerically and result from assaying a sample, and can be derived, e.g., by measuring level(s) of the biomarker(s) in the sample by an assay performed in a laboratory, by measuring the ratio or ratios of the levels of two or more of the biomarkers, or from a dataset obtained from a provider such as a laboratory, or from a dataset stored on a server. The biomarkers disclosed herein can be a nucleic acid biomarker (e.g., gene), a protein biomarker, a small molecule, and / or a cell type. In particular embodiments, the biomarker is a cell type. In particular embodiments, the sample is a skin sample from a subject. In particular embodiments, the subject has received a hematopoietic cell transplantation (HCT). In particular embodiments, the subject has cGVHD. In particular embodiments, the cGVHD is in the early lichenoid stages.
[0065] In the broadest sense, the value may be qualitative or quantitative. As such, where detection is qualitative, the systems and methods provide a reading or evaluation, e.g., assessment, of whether or not the biomarker is present in the sample being assayed. In yet other embodiments, the systems and methods provide a quantitative detection of whether the biomarker is present in the sample being assayed, i.e., an evaluation or assessment of the actual amount or relative abundance of the biomarker in the sample being assayed. In such embodiments, the quantitative detection may be absolute or, if the method is a method of detecting two or more different biomarkers in a sample, relative. As such, the term “quantifying” when used in the context of quantifying a biomarker in a sample can refer to20443-0963WO1 / INCY0626-WO1absolute or to relative quantification. Absolute quantification can be accomplished by inclusion of known concentration(s) of one or more control biomarkers and referencing, e.g., normalizing, the detected level of the biomarker with the known control biomarkers (e.g., through generation of a standard curve). Alternatively, relative quantification can be accomplished by comparison of detected levels or amounts between two or more different biomarkers to provide a relative quantification of each of the two or more biomarkers, e.g., relative to each other. The actual measurement of values of the biomarkers can be determined using any method known in the art. In some embodiments, a biomarker is detected by contacting a sample with reagents (e.g., antibodies or nucleic acid primers), generating complexes of reagent and biomarker(s), and detecting the complexes.
[0066] The reagent can include a probe. A probe is a molecule that binds a target, either directly or indirectly. The target can be a biomarker, a fragment of the biomarker, or any molecule that is to be detected. In particular embodiments, the probe includes a nucleic acid or a protein. As an example, a protein probe can be an antibody. An antibody can be a whole antibody or a binding fragment of an antibody. A probe can be labeled with a detectable label. Examples of detectable labels include fluorescent chromophores, chemiluminescent emitters, dyes, enzymes, enzyme substrates, enzyme cofactors, enzyme inhibitors, enzyme subunits, metal ions, and radioactive isotopes. The detectable label can allow visual detection of a precipitate or a color change, visual detection by microscopy, or automated detection by spectrometry, radiometric measurement or the like. In particular embodiments, the detectable label includes fluorescein and rhodamine(for fluorescence microscopy), horseradish peroxidase (for either light orelectron microscopy and biochemical detection), biotin-streptavidin (for light or electron microscopy) and alkaline phosphatase (for biochemical detection by color change).
[0067] Antibodies can be conjugated or immobilized to a solid support suitable for a diagnostic assay (e.g., beads such as protein A or protein G agarose, microspheres, plates, slides or wells formed from materials such as latex or polystyrene) in accordance with known techniques, such as passive binding. Antibodies can be conjugated to detectable labels or groups such as radioisotopes (e.g., 35S, 1251, 1311), enzyme labels (e.g., horseradish peroxidase, alkaline phosphatase), and fluorescent labels (e.g., fluorescein, Alexa, green fluorescent protein, rhodamine) in accordance with known techniques.
[0068] Examples of suitable immunoassays include immunoblotting, immunoprecipitation, immunofluorescence, chemiluminescence, electro-chemiluminescence (ECL), and / or enzyme-linked immunosorbent assays (ELISA).20443-0963WO1 / INCY0626-WO1
[0069] Further hybridization technologies that may be used are described in, for example, U.S. Pat. Nos. 5,143,854; 5,288,644; 5,324,633; 5,432,049; 5,470,710; 5,492,806; 5,503,980; 5,510,270; 5,525,464; 5,547,839; 5,580,732; 5,661,028; and 5,800,992 as well as WO 95 / 21265; WO 96 / 31622; WO 97 / 10365; WO 97 / 27317; EP 373 203; and EP 785 280.
[0070] Proteins and nucleic acids can be conjugated to or immobilized on chips, such as microarray chips. See, for example, U.S. Pat. Nos. 5,143,854; 6,087,112; 5,215,882;5,707,807; 5,807,522; 5,958,342; 5,994,076; 6,004,755; 6,048,695; 6,060,240; 6,090,556; and 6,040,138. Microarray refers to a solid carrier or support that has a plurality of molecules bound to its surface at defined locations. The solid carrier or support can be made of any material. As an example, the material can be hard, such as metal, glass, plastic, silicon, ceramics, and textured and porous materials; or soft materials, such as gels, rubbers, polymers, and other non-rigid materials. The material can also be nylon membranes, epoxyglass and borofluorate-glass. The solid carrier or support can be flat, but need not be and can include any type of shape such as spherical shapes (e.g., beads or microspheres). The solid carrier or support can have a flat surface as in slides and micro-titer plates having one or more wells. In particular embodiments, an array or microarray can include small molecules.
[0071] Binding to proteins or nucleic acids on microarrays can be detected by scanning the microarray with a variety of laser or CCD-based scanners, and extracting features with software packages, for example, Imagene (Biodiscovery, Hawthorne, CA), Feature Extraction Software (Agilent), Scanalyze (Eisen, M. 1999. SCANALYZE User Manual; Stanford Univ., Stanford, Calif. Ver 2.32.), or GenePix (Axon Instruments).
[0072] Up- or down-regulation of nucleic acids also can be detected using, for example, cDNA arrays, cDNA fragment fingerprinting, cDNA sequencing, clone hybridization, differential display, differential screening, fluorescence resonance energy transfer (FRET) detection, liquid microarrays, PCR, RT-PCR, quantitative real-time RT-PCR analysis with TaqMan assays, molecular beacons, microelectric arrays, oligonucleotide arrays, polynucleotide arrays, serial analysis of gene expression (SAGE), and / or subtractive hybridization. In particular embodiments, nucleic acids can be quantified by sequencing including: spatial transcriptomics sequencing, bulk RNA sequencing, single-cell RNA sequencing, chromatin accessibility sequencing, DNA-associated proteins sequencing, or multiplexed RNA fluorescence in situ hybridization (FISH).
[0073] As an example, Northern hybridization analysis using probes which specifically recognize one or more biomarker nucleic acid sequences can be used to determine gene expression. Alternatively, expression can be measured using RT-PCR; e.g.,20443-0963WO1 / INCY0626-WO1polynucleotide primers specific for the differentially expressed biomarker mRNA sequences are used to reverse-transcribe the mRNA into complementary DNA, which is then amplified in PCR and can be visualized and quantified. Biomarker RNA can also be quantified using, for example, other target amplification methods, such as transcription mediated amplification (TMA), strand displacement amplification (SDA), and nucleic acid sequence based amplification (NASBA), or signal amplification methods (e.g., bDNA), and the like.Ribonuclease protection assays can also be used, using probes that specifically recognize one or more biomarker mRNA sequences, to quantify gene expression.
[0074] Those skilled in the art will be familiar with numerous specific immunoassay formats and variations thereof which can be used to carry out the methods disclosed herein. See, e.g., E. Maggio, Enzyme-Immunoassay (1980), CRC Press, Inc., Boca Raton, Fla; and U.S. Pat. Nos. 4,727,022; 4,659,678; 4,376,110; 4,275,149; 4,233,402; and 4,230,797.
[0075] Embodiments disclosed herein can be used with high throughput screening (HTS). Typically, HTS refers to a format that performs at least 100 assays, at least 500 assays, at least 1000 assays, at least 5000 assays, at least 10,000 assays, or more per day. When enumerating assays, either the number of samples or the number of protein, nucleic acid, or other biomarkers assayed can be considered.
[0076] Generally HTS methods involve a logical or physical array of either the subject samples, or the protein or nucleic acid biomarkers, or both. In particular embodiments, an array can include small molecules. Appropriate array formats include both liquid and solid phase arrays. For example, assays employing liquid phase arrays, e.g., for hybridization of nucleic acids, binding of antibodies or other receptors to ligand, etc., can be performed in multiwell or microtiter plates. Microtiter plates with 96, 384, or 1536 wells are widely available, and even higher numbers of wells, e.g., 3456 and 9600 can be used. In general, the choice of microtiter plates is determined by the methods and equipment, e.g., robotic handling and loading systems, used for sample preparation and analysis.
[0077] HTS assays and screening systems are commercially available from, for example, Zymark Corp. (Hopkinton, MA); Air Technical Industries (Mentor, OH); Beckman Instruments, Inc. (Fullerton, CA); Precision Systems, Inc. (Natick, MA), etc. These systems typically automate entire procedures including all sample and reagent pipetting, liquid dispensing, timed incubations, and final readings of the microplate in detector(s) appropriate for the assay. These configurable systems provide HTS as well as a high degree of flexibility and customization. The manufacturers of such systems provide detailed protocols for the various methods of HTS.20443-0963WO1 / INCY0626-WO1
[0078] (iii) Reference Levels Derived from Control Populations. Obtained values for parameters associated with a diagnosis and therapy described herein can be compared to a reference level derived from a control population, and this comparison can indicate whether a therapy described herein should be administered to a subject. Reference levels can be obtained from one or more relevant datasets from a control population. A "dataset" as used herein is a set of numerical values resulting from evaluation of a sample (or population of samples) under a desired condition. The values of the dataset can be obtained, for example, by experimentally obtaining measures from a sample and constructing a dataset from these measurements. As is understood by one of ordinary skill in the art, the reference level can be based on e.g., any mathematical or statistical formula useful and known in the art for arriving at a meaningful aggregate reference level from a collection of individual data points; e.g., mean, median, median of the mean, etc. Alternatively, a reference level or dataset to create a reference level can be obtained from a service provider such as a laboratory, or from a database or a server on which the dataset has been stored.
[0079] A reference level from a dataset can be derived from previous measures derived from a control population. A "control population" is any grouping of subjects or samples of like specified characteristics. The grouping could be according to, for example, clinical parameters, clinical assessments, therapeutic regimens, disease status, response to treatment status, severity of condition, etc. In particular embodiments, the grouping is based on whether a subject is a responder or a non-responder. A “responder” is a subject that responds to a specified treatment for a condition. In particular embodiments, a responder experiences a reduction in cGVHD symptoms after administration with a CSF1R inhibitor (e.g. axatilimab). A “non-responder” is a subject that does not respond to a specified treatment for a condition. In particular embodiments, a non-responder does not experience a reduction in cGVHD symptoms after administration with a CSF1R inhibitor (e.g. axatilimab).
[0080] In particular embodiments, the relevant reference level for values of a particular parameter associated with a diagnosis and therapy described herein is obtained based on the value of a particular corresponding parameter associated with a diagnosis and therapy in a control population to determine whether a therapy disclosed herein has been therapeutically effective for a subject in need thereof. In particular embodiments, the relevant reference level is the reference level for a protein or nucleic acid that corresponds to the protein or nucleic acid being compared or of interest.
[0081] In particular embodiments, conclusions are drawn based on whether a sample value is statistically significantly different or not statistically significantly different from a20443-0963WO1 / INCY0626-WO1reference level. A measure is not statistically significantly different if the difference is within a level that would be expected to occur based on chance alone. In contrast, a statistically significant difference or increase is one that is greater than what would be expected to occur by chance alone. Statistical significance or lack thereof can be determined by any of various methods well-known in the art. An example of a commonly used measure of statistical significance is the p-value. The p-value represents the probability of obtaining a given result equivalent to a particular data point, where the data point is the result of random chance alone. A result is often considered significant (not random chance) at a p-value less than or equal to 0.05. In particular embodiments, a sample value is “comparable to” a reference level derived from a normal control population if the sample value and the reference level are not statistically significantly different.
[0082] As used herein, the qualifiers “inf ’ and “hi” denote expression strata defined relative to a reference distribution (e.g., within-sample quantiles, z-scores, or predetermined assay-specific cutoffs) obtained from control tissue or a validated reference set.
[0083] In particular embodiments, “hi”, “in ’, “lo”, “+” and refer to the intensity of a signal relative to negative or other populations. In particular embodiments, positive expression (+) means that a marker is detectable on a cell using flow cytometry. In particular embodiments, negative expression (-) means that the marker is not detectable using flow cytometry. In particular embodiments, “hi” means that the positive expression of a marker of interest is brighter as measured by fluorescence (using for example FACS) than other cells also positive for expression. In these embodiments, those of ordinary skill in the art recognize that brightness is based on a threshold of detection. Generally, one of skill in the art will analyze a negative control tube first, and set a gate (bitmap) around the population of interest by FSC and SSC and adjust the photomultiplier tube voltages and gains for fluorescence in the desired emission wavelengths, such that 97% of the cells appear unstained for the fluorescence marker with the negative control. Once these parameters are established, stained cells can analyzed and fluorescence recorded as relative to the unstained fluorescent cell population. In particular embodiments, and representative of a typical FACS plot, hi implies to the farthest right (x line) or highest top line (upper right or left) while lo implies within the left lower quadrant or in the middle between the right and left quadrant (but shifted relative to the negative population).
[0084] (iv) CSF-R Inhibitors. CSF1R inhibitors include any molecule or composition that targets the colony-stimulating factor 1 receptor (CSF-1R) and reduces or blocks its activity. In particular embodiments, an inhibitor includes a protein (e.g., antibody or peptide),20443-0963WO1 / INCY0626-WO1small molecule, nucleic acid, or decoy. CSFR1R is a cell-surface protein that plays a crucial role in the development, survival, and maintenance of macrophages, monocytes, and microglia. CSF1R is a receptor tyrosine kinase that activates intracellular signaling pathways when bound by its ligands, Colony Stimulating Factor 1 (CSF-1) and Interleukin-34 (IL-34). CSF-1 is a cytokine that controls the production, differentiation, and function of macrophages, and CSF1R mediates most if not all of the biological effects of this cytokine.
[0085] In particular embodiments, CSF1R (UniProtKB / Swiss-Prot: P07333.2) [Homo sapiens] includes the sequence:MGPGVLLLLLVATAWHGQGIPVIEPSVPELVVKPGATVTLRCVGNGSVEWD GPPSPHWTLYSDGSSSILSTNNATFQNTGTYRCTEPGDPLGGSAAIHLYVKDPARPW NVLAQEVVVFEDQDALLPCLLTDPVLEAGVSLVRVRGRPLMRHTNYSFSPWHGFTI HRAKFIQSQDYQCSALMGGRKVMSISIRLKVQKVIPGPPALTLVPAELVRIRGEAAQI VCSASSVDVNFDVFLQHNNTKLAIPQQSDFHNNRYQKVLTLNLDQVDFQHAGNYSC VASNVQGKHSTSMFFRVVESAYLNLSSEQNLIQEVTVGEGLNLKVMVEAYPGLQGF NWTYLGPFSDHQPEPKLANATTKDTYRHTFTLSLPRLKPSEAGRYSFLARNPGGWR ALTFELTLRYPPEVSVIWTFINGSGTLLCAASGYPQPNVTWLQCSGHTDRCDEAQVL QVWDDPYPEVLSQEPFHKVTVQSLLTVETLEHNQTYECRAHNSVGSGSWAFIPISAG AHTHPPDEFLFTPVVVACMSIMALLLLLLLLLLYKYKQKPKYQVRWKIIESYEGNSY TFIDPTQLPYNEKWEFPRNNLQFGKTLGAGAFGKVVEATAFGLGKEDAVLKVAVK MLKSTAHADEKEALMSELKIMSHLGQHENIVNLLGACTHGGPVLVITEYCCYGDLL NFLRRKAEAMLGPSLSPGQDPEGGVDYKNIHLEKKYVRRDSGFSSQGVDTYVEMRP VSTS SNDSF SEQDLDKEDGRPLELRDLLHF S SQ VAQGMAFLASKNCIHRD VAARNVL LTNGHVAKIGDFGLARDIMNDSNYIVKGNARLPVKWMAPESIFDCVYTVQSDVWSY GILLWEIFSLGLNPYPGILVNSKFYKLVKDGYQMAQPAFAPKNIYSIMQACWALEPT HRPTFQQIC SFLQEQ AQEDRRERD YTNLP S S SRSGGSGS S S SELEEES S SEHLTCCEQG DIAQPLLQPNNYQFC (SEQ ID NO: 1).
[0086] In particular embodiments, examples of CSF1R inhibitors include axatilimab, emactuzumab, and AMB-05X. Axatilimab is a humanized IgG4 antibody with high affinity to CSF1R. In particular embodiments, axatilimab includes a variable heavy chain having a complementarity determining region (CDR) heavy (H) 1 including the sequence of GFSLTTYGMGVG (SEQ ID NO: 2), a CDRH2 including the sequence of NIWWDDDKYYNPSLKN (SEQ ID NO: 3), and a CDRH3 including the sequence of IGPIKYPTAPYRYFDF (SEQ ID NO: 4); and a variable light chain having a CDR light (L) 1 including the sequence of LASEDIYDNLA (SEQ ID NO: 5), a CDRL220443-0963WO1 / INCY0626-WO1including the sequence of YASSLQD (SEQ ID NO: 6), and a CDRL3 including the sequence of LQDSEYPWT (SEQ ID NO: 7).
[0087] In particular embodiments, axatilimab includes a heavy chain including the sequence:EVTLKESGPALVKPTQTLTLTCTFSGFSLTTYGMGVGWIRQPPGKALEWLANI WWDDDKYYNPSLKNRLTISKDTSKNQVVLTMTNMDPVDTATYYCARIGPIKYPTAP YRYFDFWGQGTMVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVS WNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKR VESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQF NWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLP SSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSL SLGK (SEQ ID NO: 8) and a light chain including the sequence:DIQMTQSPSSLSASVGDRVTITCLASEDIYDNLAWYQQKPGKAPKLLIYYASS LQDGVPSRFSGSGSGTDYTLTISSLQPEDFATYYCLQDSEYPWTFGGGTKVEIKRTVA APSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 9).
[0088] Emactuzumab is a humanized monoclonal antibody that inhibits CSF1R activation. In particular embodiments, emactuzumab includes a variable heavy chain including a CDRH1 having the sequence of SYDIS (SEQ ID NO: 10), a CDRH2 having the sequence of VIWTDGGTNYAQKLQG (SEQ ID NO: 11), and a CDRH3 having the sequence of DQRLYFDV (SEQ ID NO: 12); and a variable light chain including a CDRL1 having the sequence of RASED VNTYVS (SEQ ID NO: 13), a CDRL2 having the sequence of AASNRYT (SEQ ID NO: 14), and a CDRL3 having the sequence of QQSFSYPT (SEQ ID NO: 15).
[0089] In particular embodiments, emactuzumab includes a variable heavy chain including the sequence of:QVQLVQSGAEVKKPGASVKVSCKASGYTFTSYDISWVRQAPGQGLEWMGVI WTDGGTNYAQKLQGRVTMTTDTSTSTAYMELRSLRSDDTAVYYCARDQRLYFDV WGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCD KTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYV DGVEVHNAI<TI<PREEQYNSTYRVVSVLTVLHQDWLNGI<EYI<CI<VSNI<ALPAPIEI< TISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNY20443-0963WO1 / INCY0626-WO1KTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK(SEQ ID NO: 16) and a variable light chain including the sequence of DIQMTQSPSSLSASVGDRVTITCRASEDVNTYVSWYQQKPGKAPKLLIYAASNRYTG VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQSFSYPTFGQGTKLEIKRTVAAPSVFIF PPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC (SEQ ID NO: 17).
[0090] In addition to protein inhibitors (e.g., antibodies), a CSF1R inhibitor can be a small-molecule inhibitor. In particular embodiments, a small-molecule inhibitor of CSF1R includes PLX5622, GW2580, PLX647, sotuletinib, or PLX3397 (plexidartinib). In particular embodiments, PLX5622 includes a compound having the following structure:
[0091] In particular embodiments, GW2580 includes a compound having the following structure:
[0092] In particular embodiments, PLX647 includes a compound having the following structure:20443-0963WO1 / INCY0626-WO1
[0093] In particular embodiments, sotuletinib includes a compound having the following structure:
[0094] In particular embodiments, PLX3397 includes a compound having the following structure:
[0095] (v) Compositions. Any of the CSF1R inhibitors described herein (e.g., axatilimab) can be formulated alone or in combination into compositions for administration to subjects. Additionally, nucleic acids encoding the antibodies can also be formulated into compositions for administration (e.g., nucleic acids encapsulated within nanoparticles (e.g., liposomes or polymer-based nanoparticles) and / or as part of a vector delivery system (e.g., a viral vector or plasmid). CSF1R inhibitors are referred to herein as “active ingredients”.
[0096] Salts and / or pro-drugs of the active ingredients can also be used.
[0097] A pharmaceutically-acceptable salt includes any salt that retains the activity of the active ingredient and is acceptable for pharmaceutical use. A pharmaceutically-acceptable salt also refers to any salt which may form in vivo as a result of administration of an acid, another salt, or a prodrug which is converted into an acid or salt.
[0098] Suitable pharmaceutically-acceptable acid addition salts can be prepared from an inorganic acid or an organic acid. Examples of such inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, carbonic, sulfuric and phosphoric acid. Appropriate organic acids can be selected from aliphatic, cycloaliphatic, aromatic, arylaliphatic, heterocyclic, carboxylic and sulfonic classes of organic acids.
[0099] Suitable pharmaceutically-acceptable base addition salts include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium and zinc or organic20443-0963WO1 / INCY0626-WO1salts made from N,N'-dibenzylethylene-diamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, lysine, arginine and procaine.
[0100] A prodrug includes an active ingredient which is converted to a therapeutically active compound after administration, such as by cleavage or by hydrolysis of a biologically labile group.
[0101] Exemplary generally used pharmaceutically-acceptable carriers include any and all absorption delaying agents, antioxidants, binders, buffering agents, bulking agents or fillers, chelating agents, coatings, disintegration agents, dispersion media, gels, isotonic agents, lubricants, preservatives, salts, solvents or co-solvents, stabilizers, surfactants, and / or delivery vehicles.
[0102] Exemplary antioxidants include ascorbic acid, methionine, and vitamin E.
[0103] Exemplary buffering agents include citrate buffers, succinate buffers, tartrate buffers, fumarate buffers, gluconate buffers, oxalate buffers, lactate buffers, acetate buffers, phosphate buffers, histidine buffers, and / or trimethylamine salts.
[0104] An exemplary chelating agent is EDTA (ethylene-diamine-tetra-acetic acid).
[0105] Exemplary isotonic agents include polyhydric sugar alcohols including trihydric or higher sugar alcohols, such as glycerin, erythritol, arabitol, xylitol, sorbitol, or mannitol.
[0106] Exemplary preservatives include phenol, benzyl alcohol, meta-cresol, methyl paraben, propyl paraben, octadecyldimethylbenzyl ammonium chloride, benzalkonium halides, hexamethonium chloride, alkyl parabens such as methyl or propyl paraben, catechol, resorcinol, cyclohexanol, and 3 -pentanol.
[0107] Stabilizers refer to a broad category of excipients which can range in function from a bulking agent to an additive which solubilizes the active ingredient or helps to prevent denaturation or adherence to the container wall. Typical stabilizers can include polyhydric sugar alcohols; amino acids, such as arginine, lysine, glycine, glutamine, asparagine, histidine, alanine, ornithine, L-leucine, 2-phenylalanine, glutamic acid, and threonine; organic sugars or sugar alcohols, such as lactose, trehalose, stachyose, mannitol, sorbitol, xylitol, ribitol, myoinisitol, galactitol, glycerol, and cyclitols, such as inositol; PEG; amino acid polymers; sulfur-containing reducing agents, such as urea, glutathione, thioctic acid, sodium thioglycolate, thioglycerol, a-monothioglycerol, and sodium thiosulfate; low molecular weight polypeptides (i.e., <10 residues); proteins such as human serum albumin, bovine serum albumin, gelatin or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; monosaccharides such as xylose, mannose, fructose and glucose;20443-0963WO1 / INCY0626-WO1disaccharides such as lactose, maltose and sucrose; trisaccharides such as raffinose, and polysaccharides such as dextran. Stabilizers are typically present in the range of from 0.1 to 10,000 parts by weight based on therapeutic weight.
[0108] The compositions disclosed herein can be formulated for administration by, for example, injection, inhalation, infusion, perfusion, lavage, or ingestion. The compositions disclosed herein can further be formulated for intravenous, intradermal, intraarterial, intranodal, intralymphatic, intraperitoneal, intralesional, intraprostatic, intravaginal, intrarectal, topical, intrathecal, intramuscular, intravesicular, oral and / or subcutaneous administration.
[0109] For injection, compositions can be formulated as aqueous solutions, such as in buffers including Hanks' solution, Ringer's solution, or physiological saline. The aqueous solutions can include formulatory agents such as suspending, stabilizing, and / or dispersing agents. Alternatively, the composition can be in lyophilized and / or powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
[0110] For oral administration, the compositions can be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like. For oral solid compositions such as powders, capsules and tablets, suitable excipients include binders (gum tragacanth, acacia, cornstarch, gelatin), fillers such as sugars, e.g., lactose, sucrose, mannitol and sorbitol; dicalcium phosphate, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate; cellulose preparations such as maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxy-methylcellulose, and / or polyvinylpyrrolidone (PVP); granulating agents; and binding agents. If desired, disintegrating agents can be added, such as corn starch, potato starch, alginic acid, cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate. If desired, solid dosage forms can be sugar-coated or enteric-coated using standard techniques. Flavoring agents, such as peppermint, oil of wintergreen, cherry flavoring, orange flavoring, etc. can also be used.
[0111] Compositions can be formulated as an aerosol. In particular embodiments, the aerosol is provided as part of an anhydrous, liquid or dry powder inhaler. Aerosol sprays from pressurized packs or nebulizers can also be used with a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, a dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of gelatin for use in an inhaler or insufflator may also be formulated including a powder mix of active ingredient20443-0963WO1 / INCY0626-WO1and a suitable powder base such as lactose or starch.
[0112] Compositions can also be formulated as depot preparations. Depot preparations can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
[0113] Additionally, compositions can be formulated as sustained-release systems utilizing semipermeable matrices of solid polymers including at least one active ingredient. Various sustained-release materials have been established and are well known by those of ordinary skill in the art. Sustained-release systems may, depending on their chemical nature, release one or more active ingredients following administration for a few weeks up to over 100 days. Depot preparations can be administered by injection; parenteral injection; instillation; or implantation into soft tissues, a body cavity, or occasionally into a blood vessel with injection through fine needles.
[0114] Depot compositions can include a variety of bioerodible polymers including poly(lactide), poly(glycolide), poly(caprolactone) and poly(lactide)-co(glycolide) (PLG) of desirable lactide:glycolide ratios, average molecular weights, polydispersities, and terminal group chemistries. Blending different polymer types in different ratios using various grades can result in characteristics that borrow from each of the contributing polymers.
[0115] The use of different solvents (for example, dichloromethane, chloroform, ethyl acetate, triacetin, N-methyl pyrrolidone, tetrahydrofuran, phenol, or combinations thereof) can alter microparticle size and structure in order to modulate release characteristics. Other useful solvents include water, ethanol, dimethyl sulfoxide (DMSO), N-methyl-2-pyrrolidone (NMP), acetone, methanol, isopropyl alcohol (IP A), ethyl benzoate, and benzyl benzoate.
[0116] Exemplary release modifiers can include surfactants, detergents, internal phase viscosity enhancers, complexing agents, surface active molecules, co-solvents, chelators, stabilizers, derivatives of cellulose, (hydroxypropyl)methyl cellulose (HPMC), HPMC acetate, cellulose acetate, pluronics (e.g., F68 / F127), polysorbates, Span® (Croda Americas, Wilmington, Delaware), poly(vinyl alcohol) (PVA), Brij® (Croda Americas, Wilmington, Delaware), sucrose acetate isobutyrate (SAIB), salts, and buffers.
[0117] Excipients that partition into the external phase boundary of nanoparticles such as surfactants including polysorbates, dioctylsulfosuccinates, poloxamers, PVA, can also alter properties including particle stability and erosion rates, hydration and channel structure, interfacial transport, and kinetics in a favorable manner.
[0118] Additional processing of the disclosed sustained release depot compositions20443-0963WO1 / INCY0626-WO1can utilize stabilizing excipients including mannitol, sucrose, trehalose, and glycine with other components such as polysorbates, PVAs, and dioctylsulfosuccinates in buffers such as Tris, citrate, or histidine. A freeze-dry cycle can also be used to produce very low moisture powders that reconstitute to similar size and performance characteristics of the original suspension.
[0119] In particular embodiments, the compositions include active ingredients of at least 0.1% w / v or w / w of the composition; at least 1% w / v or w / w of composition; at least 10% w / v or w / w of composition; at least 20% w / v or w / w of composition; at least 30% w / v or w / w of composition; at least 40% w / v or w / w of composition; at least 50% w / v or w / w of composition; at least 60% w / v or w / w of composition; at least 70% w / v or w / w of composition; at least 80% w / v or w / w of composition; at least 90% w / v or w / w of composition; at least 95% w / v or w / w of composition; or at least 99% w / v or w / w of composition.
[0120] Any composition or formulation disclosed herein can advantageously include any other pharmaceutically-acceptable carriers which include those that do not produce significantly adverse, allergic, or other untoward reactions that outweigh the benefit of administration. Exemplary pharmaceutically-acceptable carriers are disclosed in Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990. Moreover, compositions can be prepared to meet sterility, pyrogenicity, general safety, and purity standards as required by U.S. FDA Office of Biological Standards and / or other relevant foreign regulatory agencies.
[0121] (vi) Methods of Treatment. Following detection of the lichenoid phase of cutaneous cGVD, treatment can be initiated before the sclerotic form of the condition develops. Thus, methods disclosed herein include treating subjects (e.g., humans, veterinary animals (dogs, cats, reptiles, birds) livestock (e.g., horses, cattle, goats, pigs, chickens) and research animals (e.g., monkeys, rats, mice, fish) with compositions disclosed herein.Treating subjects includes delivering therapeutically effective amounts. Therapeutically effective amounts include those that provide effective amounts, prophylactic treatments and / or therapeutic treatments.
[0122] An "effective amount" is the amount of a composition necessary to result in a desired physiological change in the subject. Effective amounts are often administered for research purposes. Effective amounts disclosed herein can cause a statistically-significant effect in an animal model or in vitro assay relevant to the assessment of cutaneous cGVD;s development, progression, and / or resolution.20443-0963WO1 / INCY0626-WO1
[0123] A "prophylactic treatment" includes a treatment administered to a subject who does not display signs or symptoms of sclerotic cGVHD or displays only early signs or symptoms of lichenoid cutaneous cGVHD such that treatment is administered for the purpose of diminishing or decreasing the risk of developing cutaneous cGVHD further. Thus, a prophylactic treatment functions as a preventative treatment against sclerotic cutaneous cGVHD. In particular embodiments, prophylactic treatments reduce, delay, or prevent the worsening of cutaneous cGVHD.
[0124] A "therapeutic treatment" includes a treatment administered to a subject who displays symptoms or signs of lichenoid cutaneous cGVHD and is administered to the subject for the purpose of diminishing or eliminating those signs or symptoms of lichenoid cutaneous cGVHD. The therapeutic treatment can reduce, control, or eliminate the presence or activity of lichenoid cutaneous cGVHD and / or reduce control or eliminate side effects of lichenoid cutaneous cGVHD.
[0125] Function as an effective amount, prophylactic treatment or therapeutic treatment are not mutually exclusive, and in particular embodiments, administered dosages may accomplish more than one treatment type.
[0126] As used herein, the term “diminishing” is meant to describe a process by which the severity of a sign or symptom of a disorder is decreased. Importantly, a sign or symptom can be diminished without being eliminated. In a particular embodiment, the administration of compositions disclosed herein leads to the elimination of a sign or symptom, however, elimination is not required. Effective dosages are expected to decrease the severity of a sign or symptom. For instance, a sign or symptom of a disorder such as cGVHD, which can occur in multiple locations, is diminished or alleviated if the severity of the cGVHD is decreased within at least one of multiple locations.
[0127] In particular embodiments, therapeutically effective amounts provide anti-lichenoid effects. Anti-lichenoid effects include reducing or preventing skin lesions that resemble lichen planus. In particular embodiments, skin lesions can include papules, plaques, or fine scales. In particular embodiments, skin lesions are erythematous or violaceous. In particular embodiments, skin lesions are on the hand, forearm, or trunk of the subject.
[0128] In particular embodiments, therapeutically effective amounts provide anti-sclerotic effects. Anti-sclerosis effects include reducing, delaying, or preventing skin thickening, skin tightening, skin hardening, Raynaud’s phenomenon, swelling and itchiness, tel angiectasias, skin discoloration, and / or sores.
[0129] In particular embodiments, therapeutically effective amounts preserve organ20443-0963WO1 / INCY0626-WO1function in a subject.
[0130] For administration, therapeutically effective amounts (also referred to herein as doses) can be initially estimated based on results from in vitro assays and / or animal model studies. Such information can be used to more accurately determine useful doses in subjects of interest. The actual dose amount administered to a particular subject can be determined by a physician, veterinarian or researcher taking into account parameters such as physical and physiological factors including target, body weight, severity of condition, type of GVHD, stage of GVHD, previous or concurrent therapeutic interventions, idiopathy of the subject and route of administration.
[0131] Useful doses can range from 0.01 to 5 mg / kg or from 0.3 to 3 mg / kg. In other non-limiting examples, a dose can include 1 pg / kg, 15 pg / kg, 30 pg / kg, 50 pg / kg, 55 pg / kg, 70 pg / kg, 90 pg / kg, 150 pg / kg, 350 pg / kg, 500 pg / kg, 750 pg / kg, 1000 pg / kg, 0.01 to 5 mg / kg or from 0.5 to 1 mg / kg. In other non-limiting examples, a dose can include 0.3 mg / kg, 1 mg / kg, 3 mg / kg, 5 mg / kg, 10 mg / kg, 30 mg / kg, 50 mg / kg, 70 mg / kg, 100 mg / kg, 300 mg / kg, 500 mg / kg, 700 mg / kg, 1000 mg / kg or more. In particular embodiments, a dose includes 0.3 mg / kg. In particular embodiments, a dose includes 1 mg / kg. In particular embodiments, a dose includes 3 mg / kg.
[0132] Therapeutically effective amounts can be achieved by administering single or multiple doses during the course of a treatment regimen (e.g., daily, every other day, every 3 days, every 4 days, every 5 days, every 6 days, weekly, every 2 weeks, every 3 weeks, monthly, every 2 months, every 3 months, every 4 months, every 5 months, every 6 months, every 7 months, every 8 months, every 9 months, every 10 months, every 11 months or yearly). In particular embodiments, a dose is administered every 2 weeks. In particular embodiments, a dose is administered every 4 weeks.
[0133] Therapeutically effective amounts can be administered for a total length of time. In particular embodiments, a dose is administered regularly for up to a lifetime, for up to 20 years, for up to 10 years, for up to 5 years, for up to 2 years, for up to 1 year, for up to 9 months, for up to 6 months, for up to 5 months, for up to 4 months, for up to 3 months, for up to 2 months, or for up to a month. In particular embodiments, a dose is administered regularly for up to 2 years.
[0134] Therapeutically effective amounts can be administered for a specified number of courses including once, twice, thrice, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 11 times, 12 times, 20 times, 25 times, 30 times, 35 times, 40 times, or more. In particular embodiments, a dose is administered six times (i.e., six doses).20443-0963WO1 / INCY0626-WO1
[0135] In particular embodiments, the course of a treatment regimen can last for days, weeks, months, or years. In particular embodiments, the course of a treatment regimen lasts for weeks, 2 weeks, 3 weeks, months, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or a year. In particular embodiments, the course of a treatment regimen lasts for 30 weeks. In particular embodiments, the course of a treatment regimen lasts for 24 weeks.
[0136] The pharmaceutical compositions described herein can be administered by, for example, injection, inhalation, infusion, perfusion, lavage, or ingestion. Routes of administration can include intravenous, intradermal, intraarterial, parenteral, intranasal, intralesional, intramuscular, oral, subcutaneous, and / or sublingual administration.
[0137] In particular embodiments, therapeutically effective amounts are used to treat a subject. In particular embodiments, the subject has received an allogeneic hematopoietic cell transplant (HCT). In particular embodiments, the subject has signs and / or symptoms of active cGVHD. Active cGVHD is defined as the presence of signs and symptoms of cGVHD per 2014 NIH Consensus Development Project on Criteria for Clinical trials in cGVHD. In particular embodiments, the subject has refractory or recurrent cGVHD. Refractory cGVHD is identified by the development of one or more new sites of disease while being treated for cGVHD, progression of existing sites of disease despite at least 1 month of therapy for cGVHD, and / or no response to therapy despite 3 months of treatment. Recurrent cGVHD is active, symptomatic disease (after an initial response to prior therapy) as defined, based on the NIH 2014 consensus criteria, by organ-specific or global assessment or for which the physician believes that a new line of systemic therapy is required.
[0138] The Exemplary Embodiments and Example below are included to demonstrate particular embodiments of the disclosure. Those of ordinary skill in the art should recognize in light of the present disclosure that many changes can be made to the specific embodiments disclosed herein and still obtain a like or similar result without departing from the spirit and scope of the disclosure.
[0139] (vii) Exemplary Embodiments.1. A method of treating chronic GVHD (cGVHD) in a subject in need thereof, including:determining that the subject has cutaneous cGVHD that has not advanced to a sclerotic stage andadministering a therapeutically effective amount of a CSF1R inhibitor to the subject, thereby treating cGVHD in the subject in need thereof.20443-0963WO1 / INCY0626-WO12. The method of embodiment 1, wherein treating cGVHD includes reducing occurrence of sclerotic cutaneous cGVHD.3. The method of embodiment 1 or 2, wherein the determining includes performing a physical examination.4. The method of any of embodiments 1-4, wherein the determining includes:obtaining a sample from the subject,detecting one or more parameters of the sample and comparing the parameter(s) to a predetermined set of parameters derived from a reference sample; and based on the comparing, administering the therapeutically effective amount of the CSF1R inhibitor to the subject.5. The method of embodiment 4, wherein the one or more parameters includes one or more of:a proportion of macrophages expressing colony-stimulating factor 1 receptor (CSFlR)intand lysozyme (LYZ)hlin the sample;a distance between the CSFlRintLYZhlmacrophages and a basal keratinocyte (BK) layer in the sample;a proportion of CD8 T cells;a distance between CD8 T cells and CSFlRintLYZhlmacrophages and the BK layer;a distance between papillary fibroblasts and the BK layer;an expression level of IFNY, TBX21, and / or IL 17 A;an expression level of RORC;an expression level of GJB2, CD74, TGF 1, ZEB2, and / or KRT6B; an expression level of CDH1 and / or CD9;an expression level of NOS2 and / or CD163; and ablation of a papillary fraction normally adjacent an epidermal-dermal border.6. The method of embodiment 4 or 5, wherein detecting the one or more parameters includes:detecting a proportion of macrophages expressing colony-stimulating factor 1 receptor CSFlRintLYZhlin the sample;detecting a distance between the CSFlRintLYZhlmacrophages and a BK layer in the sample;comparing the proportion and distance to a reference sample;20443-0963WO1 / INCY0626-WO1wherein the subject has cutaneous cGVHD in a lichenoid stage if the proportion and distance are within the predetermined set of parameters derived from the reference sample.7. The method of embodiment 6, wherein CSFlRintLYZhlmacrophages are closer to the BK layer compared to information derived from the reference sample.8. The method of embodiment 6 or 7, wherein the proportion of CSFlRintLYZhlmacrophages are increased compared to information derived from the reference sample and the CSFlRintLYZhlmacrophages are closer to the BK layer compared to information derived from the reference sample.9. The method of any of embodiments 4-8, wherein detecting the one or more parameters includes determining in the sample a proportion of CD8 T cells.10. The method of embodiment 9, wherein the proportion of CD8 T cells is increased compared to the parameters derived from the reference sample.11. The method of any of embodiments 4-10, wherein detecting the one or more parameters includes determining in the sample a distance between CD8 T cells and CSFlRintLYZhlmacrophages and the BK layer.12. The method of embodiment 11, wherein the distance between CD8 T cells and CSFlRintLYZhlmacrophages and the BK layer is decreased compared to the parameters derived from the reference sample.13. The method of any of embodiments 4-12, wherein detecting the one or more parameters includes determining in the sample a distance between papillary fibroblasts and the BK layer.14. The method of embodiment 13, wherein the distance between papillary fibroblasts and the BK layer is decreased compared to the parameters derived from the reference sample.15. The method of any of embodiments 4-14, wherein detecting the one or more parameters includes determining in the sample an expression level of IFNY, TBX21, and / or IL 17 A.16. The method of embodiment 15, wherein the expression level of IFNY is increased compared to the parameters derived from the reference sample.17. The method of embodiment 15 or 16, wherein the expression level of TBX21 is increased compared to information derived from the reference sample.18. The method of any of embodiments 15-17, wherein the expression level of IL17A is increased compared to the parameters derived from the reference sample.19. The method any of embodiments 4-18, wherein detecting the one or more20443-0963WO1 / INCY0626-WO1parameters includes determining in the sample an expression level of RORC.20. The method of embodiment 19, wherein the expression level of RORC is increased compared to the parameters derived from the reference sample.21. The method of any of embodiments 4-21, wherein detecting the one or more parameters includes determining in the sample an expression level of GJB2, CD74, TGFpi, ZEB2, and / or KRT6B.22. The method of embodiment 21, wherein the expression level of GJB2 is increased compared to the parameters derived from the reference sample.23. The method of embodiment 21 or 22, wherein the expression level of CD74 is increased compared to the parameters derived from the reference sample.24. The method of any of embodiments 21-23, wherein the expression level of TGFpi is increased compared to the parameters derived from the reference sample.25. The method of any of embodiments 21-24, wherein the expression level of ZEB2 is increased compared to the parameters derived from the reference sample.26. The method of any of embodiments 21-25, wherein the expression level of KRT6B is increased compared to the parameters derived from the reference sample.27. The method of any of embodiments 4-26, wherein detecting the one or more parameters includes determining in the sample an expression level of CDH1 and / or CD9.28. The method of embodiment 27, wherein the expression level of CDH1 is decreased compared to the parameters derived from the reference sample.29. The method of embodiment 27 or 28, wherein the expression level of CD9 is decreased compared to the parameters derived from the reference sample.30. The method of any of embodiments 4-29, wherein detecting the one or more parameters includes determining in the sample an expression level of NOS2 and / or CD 163.31. The method of embodiment 30, wherein the expression level of NOS2 is decreased compared to the parameters derived from the reference sample.32. The method of embodiment 30 or 31, wherein the expression level of CD163 is increased compared to the parameters derived from the reference sample33. The method of any of embodiments 4-32, wherein detecting the one or more parameters includes determining in the sample an ablated cell type.34. The method of embodiment 33, wherein the ablated cell type is a papillary fraction normally adjacent an epidermal-dermal border compared to the parameters derived from the reference sample.35. The method of any of embodiments 1-34, wherein the cutaneous cGVHD is in20443-0963WO1 / INCY0626-WO1a lichenoid phase.36. The method of any of embodiments 1-35, wherein the subject has skin lesions.37. The method of embodiment 36, wherein the skin lesions include papules, plaques, or fine scales.38. The method of embodiment 36 or 37, wherein the skin lesions are erythematous or violaceous.39. The method of any of embodiments 36-38, wherein the skin lesions are on a hand, forearm, or trunk of the subject.40. The method of any of embodiments 1-39, wherein the subject is human.41. The method of any of embodiments 1-40, wherein the subject received an allogeneic hematopoietic cell transplantation (HCT).42. The method of any of embodiments 1-41, wherein the subject received an allogeneic HCT within the past 200 days.43. The method of any of embodiments 1-42, wherein the subject received an allogeneic HCT within the past 100 days.44. The method of any of embodiments 4-43, wherein the sample includes a skin biopsy.45. The method of any of embodiments 1-44, wherein the determining includes single-cell RNA sequencing, flow cytometry, immunohistochemistry, immunofluorescence, mass spectrometry, nucleic acid sequencing, or spatial transcriptomics.46. The method of any of embodiments 4-45, wherein the reference sample includes a skin biopsy from a subject that does not have cGVHD.47. The method of any of embodiments 1-46, wherein the CSF1R inhibitor includes axatilimab.48. The method of any of embodiments 1-47, wherein the therapeutically effective amount includes 0.1-5 mg / kg of the CSF1R inhibitor every 1 to 6 weeks.49. The method of any of embodiments 1-47, wherein the therapeutically effective amount includes 0.3-3 mg / kg of the CSF1R inhibitor every 2 to 4 weeks.50. The method of any of embodiments 1-47, wherein the therapeutically effective amount includes 0.3 mg / kg of the CSF1R inhibitor every 2 weeks.51. The method of any of embodiments 1-47, wherein the therapeutically effective amount includes 1 mg / kg of the CSF1R inhibitor every 2 weeks.52. The method of any of embodiments 1-47, wherein the therapeutically effective amount includes 3 mg / kg of the CSF1R inhibitor every 4 weeks.20443-0963WO1 / INCY0626-WO153. The method of any of embodiments 1-47, wherein the therapeutically effective amount includes six doses of CSF1R inhibitor.54. The method of any of embodiments 1-53, wherein the administering occurs within 1 year of receiving an allogeneic HCT.55. The method of any of embodiments 1-53, wherein the administering occurs within 30 weeks of receiving an allogeneic HCT.56. The method of any of embodiments 1-53, wherein the administering occurs within 24 weeks of receiving an allogeneic HCT.57. The method of any of embodiments 1-53, wherein the administering occurs after 100 days of receiving an allogeneic HCT.58. The method of any of embodiments 1-57, wherein the administering occurs for up to 2 years.59. The method of any of embodiments 1-58, wherein the administering includes intravenous, intradermal, intraarterial, parenteral, intranasal, intralesional, intramuscular, oral, subcutaneous, or sublingual administration.60. The method of any of embodiments 1-59, wherein the administering includes intravenous administration.61. A method of treating a subj ect in need thereof including:obtaining a sample from the subject;detecting a proportion of macrophages expressing colony-stimulating factor 1 receptor (CSFlR)intand lysozyme (LYZ)hlin the sample;determining a distance between the CSFlRintLYZhlmacrophages and a basal keratinocyte (BK) layer in the sample;comparing the proportion and distance to information derived from a reference sample; andbased on the comparing, administering a therapeutically effective amount of a CSF1R inhibitor to the subject,thereby treating the subject in need thereof.62. The method of embodiment 61, wherein the subject has cutaneous chronic graft-versus-host disease (cGVHD).63. The method of embodiment 62, wherein the cutaneous cGVHD is in a lichenoid phase.64. The method of any of embodiments 61-63, wherein the subject has skin lesions.20443-0963WO1 / INCY0626-WO165. The method of embodiment 64, wherein the skin lesions include papules, plaques, or fine scales.66. The method of embodiment 64 or 65, wherein the skin lesions are erythematous or violaceous.67. The method of any of embodiments 64-66, wherein the skin lesions are on a hand, forearm, or trunk of the subject.68. The method of any of embodiments 62-67, wherein the cutaneous cGVHD has not progressed to a sclerotic phase.69. The method of any of embodiments 61-68, wherein the distance is a relative distance as compared to a different cell type.70. The method of any of embodiments 61-69, wherein the subject is human. 71. The method of any of embodiments 61-70, wherein the subject received an allogeneic hematopoietic cell transplantation (HCT).72. The method of any of embodiments 61-71, wherein the subject received an allogeneic HCT within the past 200 days.73. The method of any of embodiments 61-72, wherein the subject received an allogeneic HCT within the past 100 days.74. The method of any of embodiments 61-73, wherein the sample includes a skin biopsy.75. The method of any of embodiments 61-74, wherein the detecting includes single-cell RNA sequencing, flow cytometry, immunohistochemistry, immunofluorescence, mass spectrometry, nucleic acid sequencing, or spatial transcriptomics.76. The method of any of embodiments 61-75, wherein the determining the distance includes immunofluorescence, immunohistochemistry, or spatial transcriptomics.77. The method of any of embodiments 61-76, wherein the reference sample includes a skin biopsy from a subject that does not have cGVHD.78. The method of any of embodiments 61-77, wherein the proportion of CSFlRintLYZhlmacrophages are increased compared to information derived from the reference sample.79. The method of any of embodiments 61-78, wherein CSFlRintLYZhlmacrophages are closer to the basal keratinocyte layer compared to information derived from the reference sample.80. The method of any of embodiments 61-79, wherein the proportion of CSFlRintLYZhlmacrophages are increased compared to information derived from the20443-0963WO1 / INCY0626-WO1reference sample and the CSFlRintLYZhlmacrophages are closer to the basal keratinocyte layer compared to information derived from the reference sample.81. The method of any of embodiments 61-80, wherein the method further includes determining in the sample a proportion of CD8 T cells.82. The method of embodiments 1, wherein the proportion of CD8 T cells is increased compared to the information derived from the reference sample.83. The method of any of embodiments 61-82, wherein the method further includes determining in the sample a distance between CD8 T cells and CSFlRintLYZhlmacrophages and the BK layer.84. The method of embodiment 83, wherein the distance between CD8 T cells and CSFlRintLYZhlmacrophages and the BK layer is decreased compared to information derived from the reference sample.85. The method of any of embodiments 61-84, wherein the method further includes determining in the sample a distance between papillary fibroblasts and the BK layer.86. The method of embodiment of embodiment 85, wherein the distance between papillary fibroblasts and the BK layer is decreased compared to information derived from the reference sample.87. The method of any of embodiments 61-86, wherein the method further includes determining in the sample an expression level of IFNY, TBX21, and / or IL17A.88. The method of embodiment 87, wherein the expression level of IFNY is increased compared to information derived from the reference sample.89. The method of embodiment 87 or 88, wherein the expression level of TBX21 is increased compared to information derived from the reference sample.90. The method of any of embodiments 87-89, wherein the expression level of IL17A is increased compared to information derived from the reference sample.91. The method of any of embodiments 61-90, wherein the method further includes determining in the sample an expression level of RORC.92. The method of embodiment 91, wherein the expression level of RORC is increased compared to information derived from the reference sample.93. The method of any of embodiments 61-92, wherein the method further includes determining in the sample an expression level of GJB2, CD74, TGFpi, ZEB2, and / or KRT6B.94. The method of embodiment 93, wherein the expression level of GJB2 is increased compared to information derived from the reference sample.20443-0963WO1 / INCY0626-WO195. The method of embodiment 93 or 94, wherein the expression level of CD74 is increased compared to information derived from the reference sample.96. The method of any of embodiments 93-95, wherein the expression level of TGFpi is increased compared to information derived from the reference sample.97. The method of any of embodiments 93-96, wherein the expression level of ZEB2 is increased compared to information derived from the reference sample.98. The method of any of embodiments 93-97, wherein the expression level of KRT6B is increased compared to information derived from the reference sample.99. The method of any of embodiments 61-98, wherein the method further includes determining in the sample an expression level of CDH1 and / or CD9.100. The method of embodiment 99, wherein the expression level of CDH1 is decreased compared to information derived from the reference sample.101. The method of embodiment 99 or 100, wherein the expression level of CD9 is decreased compared to information derived from the reference sample.102. The method of any of embodiments 61-101, wherein the method further includes determining in the sample an expression level of NOS2 and / or CD163.103. The method of embodiment 102, wherein the expression level of NOS2 is decreased compared to information derived from the reference sample.104. The method of embodiment 102 or 103, wherein the expression level of CD 163 is increased compared to information derived from the reference sample105. The method of any of embodiments 61-104, wherein the method further includes determining in the sample an ablated cell type.106. The method of embodiment 105, wherein the ablated cell type is a papillary fraction normally adjacent an epidermal-dermal border compared to information derived from the reference sample.107. The method of any of embodiments 61-106, wherein the CSF1R inhibitor includes axatilimab.108. The method any of embodiments 61-107, wherein the therapeutically effective amount includes 0.1-5 mg / kg of the CSF1R inhibitor every 1 to 6 weeks.109. The method of any of embodiments 61-107, wherein the therapeutically effective amount includes 0.3-3 mg / kg of the CSF1R inhibitor every 2 to 4 weeks.110. The method of any of embodiments 61-107, wherein the therapeutically effective amount includes 0.3 mg / kg of the CSF1R inhibitor every 2 weeks.111. The method of any of embodiments 61-107, wherein the therapeutically20443-0963WO1 / INCY0626-WO1effective amount includes 1 mg / kg of the CSF1R inhibitor every 2 weeks.112. The method of any of embodiments 61-107, wherein the therapeutically effective amount includes 3 mg / kg of the CSF1R inhibitor every 4 weeks.113. The method of any of embodiments 61-107, wherein the therapeutically effective amount includes six doses of CSF1R inhibitor.114. The method of any of embodiments 61-113, wherein the administering occurs within 1 year of receiving an allogeneic HCT.115. The method of any of embodiments 61-113, wherein the administering occurs within 30 weeks of receiving an allogeneic HCT.116. The method of any of embodiments 61-113, wherein the administering occurs within 24 weeks of receiving an allogeneic HCT.117. The method of any of embodiments 61-113, wherein the administering occurs after 100 days of receiving an allogeneic HCT.118. The method of any of embodiments 61-117, wherein the administering occurs for up to 2 years.119. The method of any of embodiments 61-118, wherein the administering includes intravenous, intradermal, intraarterial, parenteral, intranasal, intralesional, intramuscular, oral, subcutaneous, or sublingual administration.120. The method of any of embodiments 61-119, wherein the administering includes intravenous administration.121. A method of predicting that a subject having cutaneous graft-versus-host disease (cGVHD) will respond to a colony-stimulating factor 1 receptor (CSF1R) inhibitor including:measuring biomarker expression of fibroblasts;comparing the biomarker expression to a corresponding reference level; and determining the subject will respond to the CSF1R inhibitor.122. The method of embodiment 121, wherein the cGVHD is in an early lichenoid phase.123. The method of embodiment 121 or 122, wherein the CSF1R inhibitor includes axatilimab.124. The method of any of embodiments 121-123, wherein the biomarker is a nucleic acid.125. The method of any of embodiments 121-124, wherein the measuring includes obtaining a skin biopsy from the subject and quantifying biomarker expression of fibroblasts20443-0963WO1 / INCY0626-WO1from the skin biopsy.126. The method of any of embodiments 121-125, wherein the measuring biomarker expression includes performing spatial transcriptomics sequencing, bulk RNA sequencing, single-cell RNA sequencing, chromatin accessibility sequencing, DNA-associated proteins sequencing, or multiplexed RNA fluorescence in situ hybridization (FISH).127. The method of any of embodiments 121-126, wherein the measuring biomarker expression includes performing spatial transcriptomics.128. The method of any of embodiments 121-127, wherein the reference level is derived from a non-responder.129. The method of embodiment 128, wherein the fibroblasts include LGR5+ fibroblasts and the expression level of collagen genes, SPARC, and / or SFRP2 are decreased compared to the reference level.130. The method of embodiment 128 or 129, wherein the fibroblasts include papillary fibroblasts and the expression level of POSTN is decreased compared to the reference level.131. The method of any of embodiments 128-130, wherein the fibroblasts include papillary fibroblasts and the expression level of ADH1B is increased compared to the reference level.132. The method of any of embodiments 121-131, wherein the reference level is derived from a responder.133. The method of embodiment 132, wherein the fibroblasts include LGR5+ fibroblasts and the expression level of collagen genes, SPARC, and / or SFRP2 are significantly similar compared to the reference level.134. The method of embodiment 133, wherein the fibroblasts include papillary fibroblasts and the expression level of POSTN is significantly similar compared to the reference level.135. The method of embodiment 133 or 134, wherein the fibroblasts include papillary fibroblasts and the expression level of ADH1B is significantly similar compared to the reference level.136. The method of any of embodiments 121-135, wherein further including administering a therapeutically effective amount of the CSF1R inhibitor to the subject.137. The method of embodiment 136, further including measuring biomarker expression of fibroblasts after the administering.20443-0963WO1 / INCY0626-WO1138. The method of embodiment 136 or 137, wherein the administering includes intravenous, intradermal, intraarterial, parenteral, intranasal, intralesional, intramuscular, oral, subcutaneous, or sublingual administration.139. The method of any of embodiments 136-138, wherein the administering includes intravenous administration.140. The method of any of embodiments 136-139, wherein the therapeutically effective amount includes 0.1-5 mg / kg of the CSF1R inhibitor every 1 to 6 weeks.141. The method of any of embodiments 136-139, wherein the therapeutically effective amount includes 0.3-3 mg / kg of the CSF1R inhibitor every 2 to 4 weeks.142. The method of any of embodiments 136-139, wherein the therapeutically effective amount includes 0.3 mg / kg of the CSF1R inhibitor every 2 weeks.143. The method of any of embodiments 136-139, wherein the therapeutically effective amount includes 1 mg / kg of the CSF1R inhibitor every 2 weeks.144. The method of any of embodiments 136-139, wherein the therapeutically effective amount includes 3 mg / kg of the CSF1R inhibitor every 4 weeks.145. The method of any of embodiments 136-139, wherein the therapeutically effective amount includes six doses of CSF1R inhibitor.146. The method of any of embodiments 136-139, wherein the administering occurs within 30 weeks.147. The method of any of embodiments 136-139, wherein the administering occurs within 24 weeks.148. The method of any of embodiments 136-147, wherein the reference level is derived from a non-responder.149. The method of embodiment 148, wherein the expression level of IGFBP7 and / or CCND1 is decreased compared to the reference level.150. The method of embodiment 148 or 149, wherein the expression level of LGR5 is increased compared to the reference level.151. The method of any of embodiments 148-150, wherein the expression level of ACTA2, COL5A2, and / or SPON2 is decreased compared to the reference level.152. The method of any of embodiments 121-151, wherein the reference level is derived from a responder.153. The method of embodiment 152, wherein the expression level of IGFBP7 and / or CCND1 is increased compared to the reference level.154. The method of embodiment 152 or 153, wherein the expression level of LGR520443-0963WO1 / INCY0626-WO1is decreased compared to the reference level.155. The method of any of embodiments 152-154, wherein the expression level of ACTA2, COL5A2, and / or SPON2 is increased compared to the reference level.156. The method of any of embodiments 121-155, wherein the subject received a hematopoietic cell transplantation (HCT).157. A method of treating a subject with cutaneous lichenoid phase chronic graft versus host disease (cGVHD) before sclerosis occurs, the method including:obtaining a sample from the subject;determining a parameter including one or more of:a proportion of macrophages expressing colony-stimulating factor 1 receptor (CSFlR)intand lysozyme (LYZ)hlin the sample;a distance between the CSFlRintLYZhlmacrophages and a basal keratinocyte (BK) layer in the sample;a proportion of CD8 T cells;a distance between CD8 T cells and CSFlRintLYZhlmacrophages and the BK layer;a distance between papillary fibroblasts and the BK layer;an expression level of IFNY, TBX21, and / or IL17A;an expression level of RORC;an expression level of GJB2, CD74, TGF 1, ZEB2, and / or KRT6B; an expression level of CDH1 and / or CD9;an expression level of NOS2 and / or CD163; and ablation of a papillary fraction normally adjacent an epidermal-dermal bordercomparing the parameter to information derived from a reference sample; and based on the comparing, administering a therapeutically effective amount of a CSF1R inhibitor to the subject,thereby treating the subject with cutaneous lichenoid phase chronic graft versus host disease (cGVHD) before sclerosis occurs.EXPERIMENTAL EXAMPLES
[0140] Example 1: High-resolution spatial transcriptomic analysis of cutaneous chronic graft-versus-host disease (cGVHD) defines aberrant macrophage infiltration and20443-0963WO1 / INCY0626-WO1parameters of response to colony stimulating factor-1 receptor (CSF-1R) inhibition
[0141] Chronic graft-versus-host disease (cGVHD) is a frequent and morbid immune-mediated complication of allogeneic hematopoietic cell transplantation (HCT), with skin the most common target organ. Sub-cellular spatial transcriptomics was undertaken to dissect immune networks involved in human lichenoid skin cGVHD early after HCT, then before and after treatment with the colony stimulating factor-1 receptor (CSF-lR)-blocking antibody axatilimab in later sclerotic phases. A lichenoid cGVHD state was identified, hallmarked by a pathogenic triad of alternatively-activated CSFlRintLYZhlmacrophages, CD8 T-cells, and abnormal basal keratinocytes with fibroblast trans-differentiation. These data confirm the central role of donor CSF1R+macrophages in human cGVHD and downstream impacts that promote abnormal epithelial and fibroblast differentiation in tissue.
[0142] Allogeneic HCT is a highly effective and curative therapy for malignant bone marrow and failure syndromes. Despite optimal donor selection and prophylactic immunosuppression, many patients develop graft-versus-host disease (GVHD), the donor-derived immune system attacking recipient tissue. cGVHD affects 30-50% of patients after HCT and is the major source of morbidity and mortality in long-term HCT survivors. Skin is the most frequent site of cGVHD (Arora et al., Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation. 2016, 22(3):449-55), and includes superficial lichenoid lesions and deep, fibrotic sclerosis which may arise sequentially (Jagasia et al., Journal of the American Society for Blood and Marrow Transplantation. 2015, 21 (3):389-401 el).
[0143] Cutaneous cGVHD features both monocyte / macrophage and T cell infiltration. Preclinical models have demonstrated colony stimulating factor-1 receptor (CSF-1R)-dependent tissue macrophage accumulation with associated fibrosis, leading to clinical studies and the recent FDA approval of the anti-CSF-lR antibody axatilimab for refractory disease (Wolff, et al. N Engl J Med. 2024, 391(11): 1002-1014). To date, little is known regarding the role of macrophage differentiation and downstream effects in human cGVHD, particularly within tissue. High-resolution spatial transcriptomics was used to interrogate skin in early lichenoid and late sclerotic phases of cGVHD, the latter before and after treatment with axatilimab in the pivotal AGAVE-201 registration trial. A putative pathologic triad of CD8 T cells and CSFlRintLYZhlmacrophages colocalized with aberrant keratinocytes expressing genes involved in immune cell recruitment and antigen presentation, generating disordered fibroblasts with evidence of epithelial- and macrophage-mesenchymal transition, potential harbingers of fibrosis. These data confirm the central role of macrophages in human20443-0963WO1 / INCY0626-WO1cGVHD and downstream effects resulting in disordered epithelial and fibroblast differentiation.
[0144] Methods. Skin sample selection. The first set of formalin-fixed paraffin embedded (FFPE) samples of skin biopsies obtained from hematopoietic cell transplantation (HCT) patients were previously obtained as part of clinical protocols (Fred Hutch IRB #8789). Biopsies were taken from patients with clinically diagnosed lichenoid skin cGVHD, with subclinical skin cGVHD identified only retrospectively on pathology review, without cGVHD 12 months post-HCT, and prior to HCT as a baseline sample. Each sample was independently evaluated by a pathologist for cGVHD-defining histologic features. The second set of FFPE skin biopsy samples were provided by Incyte, Inc. from patients enrolled in the Agave-201 phase II trial of axatilimab for recurrent or refractory cGVHD (Wolff, et al. (2024) N Engl J Med 391(11): 1002-1014). Biopsies were taken at pre-axatilimab baseline and at cycle 3 day 1 and represented patients from multiple treatment dose trial arms, including 0.3 mg / kg every 2 weeks, 1 mg / kg every 2 weeks, and 3 mg / kg every 4 weeks. All included patients had sclerotic skin cGVHD in addition to other potential organ sites, and samples were obtained from equal proportions of patients whose cGVHD responded vs. did not respond to axatilimab, although this was based on overall response criteria and no patients had a skin response as scored by conventional National Institutes of Health (NIH) cGVHD consensus criteria (Jagasia, et al. (2015) Biol Blood Marrow Transplant 21(3):389-401. el).
[0145] Xenium sample preparation and processing. Per lOx Genomics manufacturer instructions, FFPE samples were sectioned onto Xenium slides and hematoxylin and eosin (H&E) staining was performed. Slides were deparaffinized and decrosslinked for fixation and permeabilization and processed per Xenium vl protocol. For the first set of skin samples, hybridization was performed with a 400-gene probe set comprised of a 280-gene breast panel base + 120 custom genes (FIG. 1). For the second set of skin samples, hybridization was performed with a 480-gene probe set comprised of a 380-gene immune-oncology panel base + 100 custom genes (FIG. 2). Samples were processed on a Xenium Analyzer.
[0146] Histology Imaging. H&E-stained samples mounted onto Xenium slides were imaged at the Fred Hutchinson Cancer Center Imaging Core on a TissueFAXS microscope at 40x magnification. Digital images were obtained using TissueFAXS Viewer 7.1.7.141 software.
[0147] Xenium data processing, cell segmentation, and basic cell type identification. Cells were segmented with Proseg (Jones, et al. (2024) bioRxiv20443-0963WO1 / INCY0626-WO1doi: 10.1101 / 2024.04.25.591218), a probabilistic method which models gene expressions and infers plausible cell boundaries based on the spatial distribution of transcripts. For the purposes of analysis, cells with fewer than 10 assigned transcripts were discarded. Jointly, across all samples, Uniform Manifold Approximation and Projection (UMAP) (Mclnnes, et al. (2018) arXiv preprint arXiv: 1802.03426) projections were computed, and cells were clustered using Leiden (Traag, et al. (2019) Sci Rep 9(1): 5233). Broad cell types were defined manually by inspecting the spatial distributions and aggregate gene expression patterns of the clusters. For example, keratinocyte subtypes were identified both by their shift in expressed sets of keratin genes and by the spatial relationship of the layers formed. As part of this process, “abnormal” clusters of spinous and basal keratinocytes that were present only in certain cGVHD samples, and distinct from the main keratinocyte clusters in UMAP space were labeled. These broad cell types were further refined based on positive expression of selected marker genes.
[0148] Gene expression analysis. Xenium spatial data was converted into a single Seurat object containing all twelve samples’ cells. Gene expression profiles were visualized in a low dimensional embedding using Seurat’s implementation of the UMAP algorithm, and further analysis was performed on major individual cell types. Cluster markers were identified using Seurat’s default non-parametric Wilcoxon rank-sum test (FindMarkers and FinAllMarkers). Cell type identities were applied to clusters based on either cross-referenced cell type annotation or on dominant marker gene expression . Differential gene expression analysis between experiment groups was performed within respective clusters using a pseudobulked approach with DESeq2 in order to equally weight patient samples with differing cell numbers; genes included in analyses achieved baseMean >100 and padj <0.05.
[0149] Cell proximity analysis. The proximity between cell types was measured by building a spatial neighborhood graph using Delaunay triangulation and then computing the expected number of steps in a random walk before a cell of the target type is encountered. In Markov chain analysis this is referred to as the expected absorption time and can be computed efficiently by solving a spare linear system. The proximity measure can also be normalized to account for the local cell type composition by dividing by the expected absorption time after an initial k step preliminary random walk (where was set to k=100 in practice), which can be thought of as a local shuffle of the cell positions to get a background distribution to which to compare.
[0150] Spillover gene reconciliation. Although Proseg has superior cell segmentation ability compared to other available cell segmentation algorithms (Jones, eta!. (2024) bioRxiv20443-0963WO1 / INCY0626-WO1doi: 10.1101 / 2024.04.25.591218), there was occasional cases of gene expression “spillover” between adjacent cells, in which a given cell type appeared to express improbable genes. In general, the levels of these transcripts were far lower than the expression of the transcripts in bona fide cell lineages expressing these genes. In marker gene analysis and differential gene expression analysis, the genes lists were manually audited and putative spillover genes were discarded from further analysis.
[0151] Results. Cutaneous lichenoid cGVHD segregates by degree of immune cell infiltration. Across eight skin biopsies from seven patients with cGVHD (one patient represented by biopsies obtained from two points in cGVHD course) and four non-cGVHD control biopsies (one from a patient at 12 months post-HCT and three at pre-HCT baseline), major skin cell types were identified based on canonical gene expression and tissue location using a 400-gene lOx Genomics Xenium probe panel (FIGs. 1-2). These included dominant populations of fibroblasts, keratinocytes, macrophages, and T cells, and smaller proportions of endothelial cells, adipocytes, melanocytes, pericytes, and sweat gland cells with variable abundance between samples (FIG. 3A-3B). Four cGVHD samples had elevated abundance of macrophages / dendritic cells (DCs) and T cells compared to either the Control or other cGVHD samples, after normalization to basal keratinocyte (BK) numbers (FIG. 3 A). cGVHD specimens were thus termed “High Infiltration” (herein HI) and “Low Infiltration” (herein LI). The abundance of immune cells in the LI group did not significantly differ from that of the Control group (FIG. 3A). Computational spatial reconstruction demonstrated dominant keratinocyte populations, grossly with T cells and macrophages juxtaposed near the keratinocyte layer and fibroblasts distributed both near the epidermis and throughout the dermis. The analysis focused on cells consistent across samples: macrophages, T cells, keratinocytes, and fibroblasts.
[0152] Highly immune cell-infiltrated cutaneous lichenoid cGVHD is characterized by CSFlRintLYZhlmacrophages. UMAP clustering of myeloid cells demonstrated four macrophage clusters: a CSF1R111cluster expressing high levels of MRC1, CD163, and CD14; a cluster termed CSFlRintLYZhlexpressing intermediate levels of CSF1R transcript with high LYZ, FCGR3A, and HLA-DQA1 expression; a small cluster expressing CCL8 (“CCL8 Mac”); and a cluster expressing modest levels of both myeloid markers CD68 and CD 163 and multiple collagen genes, MMP2, LUM, and PDGFRA / B classified as putatively transdifferentiating macrophages undergoing macrophage-mesenchymal transition (MMT) (termed “Fibro Mac”) (FIG. 5). Expression of NOS2, a classically activated macrophage gene, was sparse. In contrast, expression of CD 163 was very high, supporting these20443-0963WO1 / INCY0626-WO1macrophages being alternatively activated, or M2 -type. Two DC clusters were present: presumptive cDCls expressing CLEC9A and cDC2s expressing CLEC10A, FCGR3A, and HLA-DQA1.
[0153] While CSF1R111macrophages were present irrespective of cGVHD, the CSFlRintLYZhlpopulation was the predominant subset differentially present in HI compared to Control skin (FIGs. 4A-4B). There were also increased numbers of CCL8 macrophages in the HI samples (p=0.0436), a population which has been suggested to facilitate myeloid and T cell recruitment in renal transplantation rejection (Dangi, et al. (2022) J Am Soc Nephrol 33(10): 1876-1890). Proximity “walk” analysis, measuring the average cell width distance from BKs to the first encountered macrophage of each respective cluster, demonstrated that CSFlRintLYZhlmacrophages were the closest macrophages to the BK layer in HI samples (compared to Control distance, p=0.0003), and HI CCL8 macrophages were also closer to the BK layer (p=0.0035) (FIG. 4C). CSF1R111macrophages, common to all sample groups, did not differ in BK proximity. These data highlight CSFlRintLYZhland CCL8 macrophage subsets as defining highly immune-infiltrated lichenoid cGVHD skin.
[0154] In pseudobulked differential gene expression analysis of the four macrophage clusters between HI and Control, HI cells expressed higher levels of MHC class II and associated genes as well as higher levels of LYZ (FIG. 4D). HI macrophages across multiple clusters expressed higher FTH1 encoding ferritin heavy chain (associated with TGF-P expression, M2 macrophage polarization, and transdifferentiation into fibroblasts (Tomay, et al. (2019) J Transl Med 17(1):237; Patino, et al. (2023) JCI Insight 8(l):el 59235)) and CTSB encoding cathepsin B (associated with M2 polarization and fibroblast-derived collagen deposition in bronchiolitis obliterans syndrome (BOS) after lung transplantation (Morrone, et al. (2021) Eur Respir J 57(5):01416-2020; Lu, et al. (2022) Biomed Pharmacother 156:113947)). Conversely, CSF1R111macrophages from Control patients expressed higher levels of IGF 1, which is associated with reduced monocyte tissue infiltration and IL-4-influenced M2 differentiation (Snarski, et al. (2022) Arterioscler Thromb Vase Biol 42(2): 113-126; Shan, et al. (2022) Cell Mol Immunol 19(11): 1263-1278; Ju, et al. (2024) Open Med (Wars) 19(l):20240912).
[0155] CD8 T cells closely associate with basal keratinocytes and CSFlRintLYZhlmacrophages. Skin T cells segregated into major CD4, CD8, Treg, and NKT cell clusters. CD8 T cells and NKT cells were more abundant in HI compared to Control (FIG. 4E), with CD8 T cells in HI groups being the closest lymphoid cells to the BK layer (FIG. 4F). Both type-1 (IFNG+and Tbet+) and type-17 (IL-17+and RORC+) T cells were present, although20443-0963WO1 / INCY0626-WO1only the former dominated in HI skin (FIG. 6). CD4 T cell abundance and BK proximity were equivalent between HI and Control groups. To discern prospective in situ interactions between these T cells and skin macrophage subsets, a “round trip” proximity measurement consisting of the sum of bidirectional median distances between cell types was employed. The round-trip distance between CSFlRintLYZhlmacrophages and each T cell type was closer within the HI samples (FIG. 4G). Within HI skin, CSFlRintLYZhlmacrophages and CD8 T cells were the closest of any macrophage-T cell pair. CSF1R111macrophages and CCL8 macrophages likewise showed closer distances to all T cell types in the HI group compared to the Control. Within HI skin, CD8+ T cells had the closest mean proximity to each macrophage type, followed by CD4 T cells, then Tregs, then NKT cells. These data are consistent with CD8 T cells and CSFlRintLYZhlmacrophages representing the major pathogenic immune infiltrate in lichenoid cGVHD.
[0156] Cutaneous cGVHD is associated with highly aberrant fibroblast differentiation. Within fibroblasts, a papillary population near the epidermis and seven reticular populations within the dermis was identified. These included three large populations: 1) a collagen-rich cluster with gene profiles analogous to LGR5+ fibroblasts (as defined by Gur, et al. (2022) Cell 185(8): 1373-1388. e20 and termed “LGR5 -equivalent” due to the absence of LGR5 in this Xenium probe set), 2) a cluster specifically expressing DMKN and MLPH (encoding dermokine and melanophilin respectively, both implicated in epithelial-mesenchymal transition (EMT) (Potluri, et al. (2022) JCI Insight 7(9):el52011; Wei, et al. (2024) J Cancer 15(17):5828-5838)) and CRISPLD2 implicated in TGF-P response (Ding, etal. (2024) Rheumatology (Oxford) keae541) and overexpressed in fibroblasts in systemic sclerosis (Malaab, et al. (2022) Ann Rheum Dis 81 (2):268— 277) and idiopathic pulmonary fibrosis (Chen, et al. (2024) Heliyon 10(7):e28088) (cluster termed “DMKN”), and 3) a CD74hlpopulation co-expressing HLA-DQA1 and AIF1 (encoding macrophage protein IB Al) suggesting antigen presentation capability and potentially the product of MMT (Abu El-Asrar, et al. (2023) Int J Mol Sci 24(17): 13510). A medium-sized CLEC3B population was present that contributes to healing and collagen metabolism (Kirkwood, et al. (2021) FASEB J 35(4):e21285; Chen, et al. (2022) Sci Transl Med 14(645):eabj9152). Three smaller clusters included IGF1+ and LRRC15+ clusters both putatively representing myofibroblasts (Culley, et al. (2021) Front Cell Dev Biol 9:628039; Krishnamurty, et al. (2022) Nature 611(7934): 148-154) and an EMX2+ cluster putatively representing fibroblasts reprogramming into other cell lineages (FIG. 8A).
[0157] Papillary fibroblasts were depleted in the LI group compared to Control20443-0963WO1 / INCY0626-WO1(p=0.0270), and both cGVHD groups had decreased LGR5-equivalent reticular fibroblasts (HI vs. Control p=0.0073, LI vs. Control p=0.0011) (FIGs. 7A, 7B). Pertinent to cutaneous cGVHD, LGR5+ fibroblasts are also decreased in systemic sclerosis (Gur, et al. (2022) Cell 185(8): 1373-1388. e20). Although not achieving statistical significance, both the HI and LI groups contained samples enriched for DMKN fibroblasts, notable given the known role of TGF-P in fibrosis during cGVHD (Alexander, et al. (2014) J Clin Invest 124(10):4266-4280). The papillary fibroblast location was perturbed in HI skin, with a mean 1.974 logio steps from the BK layer, compared to 1.631 in Control (p=0.0143) (FIG. 7C). One major reticular population, CD74hlfibroblasts, although of similar abundance between groups, were located closer to the BK layer in HI vs. Control (mean 2.249 vs. 2.676 logio steps, p=0.0247). Given this cluster’s expression of MHC class II and the potential for antigen presentation, the increased proximity to BKs may reflect immune activation in lichenoid cGVHD. Conversely, CLEC3B+ fibroblasts (implicated in healing and tissue organization) from Control samples were closer to BKs than those from HI samples (mean 2.288 vs. 2.892 logio steps, p=0.0213).
[0158] Fibroblast differential gene expression between HI and Control samples bore evidence of potential immune modulatory capability. Fibroblasts as a whole in HI samples had higher CD74 and CD68 expression (FIG. 8B). This was recapitulated within papillary fibroblasts, along with higher CD74 expression in LGR5-equivalent and CLEC3B reticular fibroblasts (FIG. 7D). In cancer-associated fibroblasts (CAFs), lower CD68 expression is associated with an immune-suppressive CCL17- and CCL22-expressing phenotype and Treg recruitment (Zhao, et al. (2020) Am J Pathol 190(4): 886-899). Thus, elevated CD68 expression in the context of cGVHD may contribute to ongoing immune cell infiltration. Separate CAF fate-mapping and transcriptional studies suggest that some CD68hlfibroblasts represent the product of MMT (Tang, et al. (2022) Adv Sci (Weinh) 9(l):e2101235). With respect to CD74, CD74-expressing CAFs also appear able to activate CD4 T cells in an antigen-specific fashion (Elyada, et al. (2019) Cancer Discov 9(8): 1102-1123). CD74 is notably highly expressed in skin fibroblasts from patients with diffuse systemic sclerosis, a disorder recapitulating some disease elements of skin cGVHD (Banos-Hernandez, et al. (2021) Cent Eur J Immunol 46(3): 375— 383), and CD74 engagement facilitates TGF-pi expression in primary joint capsule fibroblasts associated with post-traumatic joint contracture (Zhang, et al. (2021) Int J Biol Sci 17(7): 1837-1850; Zhang, et al. (2021) Aging (Albany NY) 13 (4): 5804— 5823). Additionally, Hl’s reticular LGR5 -equivalent cluster expressed higher COL6A1 levels (akin to HI Fibro Mac differential expression of COL6A1, FIG.4D), which is associated with myofibroblast activation mediating dermal, lung, and liver20443-0963WO1 / INCY0626-WO1fibrosis (Williams, et al. (2022) FEBS J 289(13):3603-3629). Together, these data depict a highly perturbed fibroblast state in lichenoid cGVHD with the potential for fibroblast-driven immunomodulation.
[0159] Keratinocytes differentiation in immune cell-infiltrated lichenoid cGVHD is highly disordered. Keratinocytes were classified by epidermal layer. BKs and spinous keratinocytes (SKs) each contained subsets present essentially only in HI samples and termed “abnormal BKs” (ABKs) and “abnormal SKs” (ASKs), in contrast to “normal BKs” (NBKs) and “normal SKs” (NSKs) existing across all groups (FIG. 9A). NBKs prominently expressed the immune regulator CXCL14 and decorin-encoding DCN, a TGF-pi neutralizer inhibiting liver fibrosis (Chen, et al. (2020) Biomed Res Int 2020:8815904; Fullar, et al. (2017) Pathol Oncol Res 23(2):287-294) (FIG. 9B). In contrast, ABKs had higher expression of CD74, GJB2 encoding gap junction protein connexin-26, stress-activated KRT6B, and EMT-associated ZEB2 and TGFB1 (Zhang, et al. (2019) Cells 8(8):807). Compared to NSKs, ASKs had differential expression patterns in similar genes as well as lower expression of E-cadherin-encoding CDH1 and its regulator CD9 (likewise suggestive of increased EMT) (Masse, et al. (2014) Arch Dermatol Res 306(2):201-208; Zeitvogel, et al. (2017) Sci Rep 7(1): 11847). Granular keratinocyte (GK) markers were largely distinct from other keratinocytes.
[0160] NBK HI vs. Control DEGs were reminiscent of the genes characterizing ABKs and ASKs (FIG. 9C). These included GJB2, which is associated with psoriasiform epidermal hyperproliferation and increases immune cell infiltration, such that ectopic keratinocyte GJB2 expression is sufficient to recruit immune cells in epidermal injury models (O'Shaughnessy et al., International journal of molecular sciences. 2021, 22(11); and Djalilian et al., J Clin Invest. 2006, 116(5): 1243-53). The higher expression of CD74 suggests the potential for antigen presentation and keratinocyte-induced IFNG-producing CD4+ T cells (Tamoutounour et al., Proc Natl Acad Sci U S A. 2019, 116(47):23643-23652); this differential expression was also evident in SKs and GKs. Finally, HI NBKs had lower CXCL14 expression. CXCL14 can inhibit the CXCR4-CXCL12 interaction in skin to inhibit immune cell recruitment, including T cells (Nakajima et al., Journal of Cutaneous Immunology and Allergy. 2023, 6(6):225-230). These patterns are each established in human psoriasis (Nakajima et al., Journal of Cutaneous Immunology and Allergy. 2023, 6(6):225-230), which shares many clinical and putative mechanistic features with skin cGVHD.
[0161] In analysis of total BKs (NBKs and ABKs) and the distance to major immune cells as univariate linear functions of BK gene expression, GJB2, alongside chemokine20443-0963WO1 / INCY0626-WO1CXCL16 (whose receptor CXCR6 is in T cells) and alarmin S100A8, was associated with closer proximity to T cells and macrophages, with some relationships extending to non-cGVHD controls (FIG. 9D). Conversely, BK expression of CXCL14 and keratinocyte migration- / proliferation-promoting AQP3 were associated with more distant immune cells.
[0162] When gene expression was dichotomized as expressed vs. non-expressed, BKs expressing GJB2 in HI samples correlated with closer proximity to CD8 T cells (the highest magnitude of impact) plus Tregs and CD4 T cells, as well as closer T cell subsets expressing TBX21, RORC, IFNG, and IL17A (FIGs. 9E, 9F). CSFlRintLYZhiand CCL8 macrophages were also closer to GJB2+than GJB2negBKs. Although overall GJB2 expression was higher in BKs from HI samples than from Control samples, GJB2+BKs in Control samples had closer proximity to many T cell types compared to GJB2negBKs. Similar, though less profound, trends were observed according to BK CD74 expression status, most apparent in TBX21+and IFNG+T cells and in CSFlRintLYZhlmacrophages. Conversely, CXCL14 expression (less expressed in HI BKs than Control) was associated with more distant immune subsets. These associations are highly suggestive of a contribution of keratinocytes themselves to the pathogenesis of cGVHD, consistent with the centrality of CSFlRintLYZhlmacrophages and CD8+ T cells in disease.
[0163] Successful therapeutic CSF-1R inhibition is associated with low-activation states of fibroblasts at baseline. The pre- and post-treatment skin biopsies from patients with steroid-refractory multisystem cGVHD (all with clinically diagnosed skin sclerosis) enrolled on the AGAVE-201 clinical trial (Wolff, et al. (2024) N Engl J Med 391(11): 1002-1014) of axatilimab, an antibody blocking the CSF-1R (FIG. 10) were analyzed next. Five clinical responder and five clinical non-responder patients were included (response defined as having an objective response in any organ per NIH cGVHD consensus criteria (Jagasia, et al. (2015) Biol Blood Marrow Transplant 21 (3):389— 401.el) within the trial primary endpoint period of six cycles, 24 weeks). Although all ten patients were clinically diagnosed with sclerosis, pre-axatilimab baseline biopsies showed overt histologic sclerosis (score >2) in only three patients, with four having a score of 1, and the remaining three with no histological sclerosis identified, potentially related to biopsy site selection. A 480-gene Xenium probe panel separate from the panel used in the lichenoid studies was utilized (FIG. 11).
[0164] Discussion. Cutaneous cGVHD is a persistent and highly morbid complication among HCT survivors. These data highlight the abundance of aberrant CSF1R+tissue macrophages (CSFlRintLYZhl) in lichenoid cutaneous cGVHD and its colocalization in a putatively pathogenic triad with CD8 T cells at the BK interface culminating in highly20443-0963WO1 / INCY0626-WO1disordered keratinocyte and fibroblast differentiation and mesenchymal transition, which are potential harbingers of fibrosis. The deletion of CSF-1R+macrophages with axatilimab in more sparsely immune-infiltrated sclerotic phases of cGVHD was associated with clinical response. The data defines an evolution in disease from lichenoid manifestations occurring relatively early post-HCT into sclerosis, a difficult-to-treat and difficult-to-reverse manifestation, including reduction in LGR5+fibroblasts. These data confirm the central role of macrophages in multiple forms of skin cGVHD and, based on the lichenoid stage findings, show that early CSF-1R inhibition represents an optimal therapeutic window.
[0165] Preclinical models of both sclerosis and BOS have demonstrated the centrality of CSF-1R+macrophages, a final common immune pathway mediator, in establishing cGVHD fibrosis. CSF-1R inhibition prevents disease and accumulation of CSF-1R+macrophages in end-organ tissue, essentially eliminating fibrosis (Alexander, et al. (2014) J Clin Invest 124(10):4266-4280). Indeed, this is the basis for the therapeutic use of CSF-1R-targeting axatilimab for cGVHD. The aberrant CSFlRintLYZhlmacrophages’ high LYZ expression with accompanying FCGR3A (encoding CD 16) expression suggests that these may represent recently-arrived monocyte-derived macrophages (Lei, et al. (2022) Cell Mol Immunol 19(12): 1333-1346). Ongoing understanding of these CSFlRintLYZhlmacrophages may provide further therapeutic opportunities to target cGVHD-inducing macrophages while potentially preserving beneficial monocyte functions in antimicrobial immunity and / or wound healing (Adams, et al. (2025) Blood 145(10): 1010-1021).
[0166] While preclinical studies have been critical for identifying the role of macrophages in cGVHD (Alexander, et al. (2014) J Clin Invest 124(10):4266-4280; Adams, et al. (2025) Blood 145(10): 1010-1021), the degree of infiltration in these preclinical models was most consistent with the lichenoid skin samples in the present cohorts. The response of sclerotic disease to CSF-1R inhibition, despite relatively sparse and qualitatively different macrophage subsets compared to earlier disease, is intriguing and suggests a systemic response may be mediating clinical improvement in responders. Conversely, these data would support intervening earlier during lichenoid phases of disease, ideally in patients with high levels of infiltrate seen in routine diagnostic biopsies. Profound, previously unrecognized abnormalities in keratinocyte and fibroblast differentiation in patients with both lichenoid and sclerotic cGVHD, were observed, consistent with hitherto unappreciated effects of aberrant tissue macrophage infiltration on epithelial and stromal function, strongly supporting the presence of donor-derived MMT post-HCT.20443-0963WO1 / INCY0626-WO1
[0167] Example 2: Additional description and analysis of work described in Example 1
[0168] Skin with confirmed lichenoid cGVHD histopathology segregated into high (HI) and low (LI) immune cell-infiltrated tissue that reflected macrophage and T cell abundance. Non-cGVHD biopsies collected before or after HCT served as controls. While CSF1R111macrophages were equally abundant irrespective of cGVHD, an alternatively activated CSFlRintLYZhlpopulation was the predominant subset differentially infiltrating HI skin (p=0.0011) and resided closest to basal keratinocytes (BKs) by proximity analysis. CD8 T cells were the dominant infiltrating lymphocytes distinctive to HI skin (p=0.0016) and in close bidirectional proximity to CSFlRintLYZhlmacrophages (p<0.0001). These immune cells were, in turn, located adjacent to BKs, forming a pathogenic triad.
[0169] Highly aberrant basal and spinous keratinocyte differentiation was seen deep within the epidermis in cGVHD skin. Close proximity of CSFlRintLYZhlmacrophages and type-1 and type-17 T cells (expressing IFNG, TBX21 and IL17A, RORC respectively) to these BKs was associated with increased transcripts associated with immune cell recruitment (GJB2) and antigen presentation (CD74), suggesting immunomodulatory functions of keratinocytes in cGVHD. These HI keratinocytes bore high TGFB1 and ZEB2 and low CDH1 expression, consistent with epithelial-mesenchymal transition. Within the dermis, major fibroblast subsets were ablated during cGVHD, including the papillary fraction abutting the epidermal-dermal border and the dominant reticular LGR5+-equivalent subset (p=0.0376), pivotal to tissue organization and homeostasis. A proportion (5-10%) of residual skin fibroblasts were donor origin and expressed features of macrophage-mesenchymal transition.
[0170] Pre- and post-treatment skin biopsies from patients with steroid-refractory sclerosis enrolled on the AGAVE-201 study of axatilimab were analyzed next. As opposed to lichenoid cGVHD, cellular infiltration, including CSF-1R+macrophages, was relatively sparse in this late phase of disease. Nevertheless, overall response to axatilimab was associated with a significant depletion of macrophages, including CSF-1R111and CSFlRintLYZhlsubsets and concurrent increases in FoxP3+regulatory T cells in the skin (p<0.05), suggesting that a systemic regulatory response may mediate clinical response. These immune subsets were unchanged in non-responders. LGR5+fibroblasts, the main reticular population, demonstrated increased baseline collagen, M2 and myofibroblastpolarizing and collagen-amplifying gene transcripts in axatilimab non-responders. Similarly, papillary fibroblasts from non-responders expressed high baseline levels of profibrogenic20443-0963WO1 / INCY0626-WO1TGF-P target genes. In contrast, papillary fibroblasts were characterized by lower activation states in responders.
[0171] These data highlight a specific, aberrant CSF1R+tissue macrophage population in lichenoid skin cGVHD and its colocalization in a putative pathogenic triad with CD8 T cells at the BK interface culminating in profound, previously unrecognized abnormalities in keratinocyte and fibroblast differentiation and mesenchymal transition — harbingers of fibrosis. The deletion of CSF-1R+macrophages with axatilimab in more sparsely infiltrated sclerotic phases of cGVHD was associated with Treg expansion and clinical response. These data confirm the central role of macrophages in human cGVHD, provide a mechanism of response to CSF-1R inhibition, and suggest treatment at the lichenoid stage represents an optimal therapeutic window.
[0172] (ix) Closing Paragraphs. The nucleic acid and amino acid sequences provided herein are shown using letter abbreviations for nucleotide bases and amino acid residues, as defined in 37 C.F.R. §1.831-1.835 and set forth in WIPO Standard ST.26 (implemented on July 1, 2022). Only one strand of each nucleic acid sequence is shown, but the complementary strand is understood as included in embodiments where it would be appropriate.
[0173] " Binds" refers to an association of a binding domain (of, for example, an antibody) to its cognate binding molecule with an affinity or Ka(z.e., an equilibrium association constant of a particular binding interaction with units of 1 / M) equal to or greater than 105M’1, while not significantly associating with any other molecules or components in a relevant environment sample. Binding domains may be classified as "high affinity" or "low affinity". In particular embodiments, "high affinity" binding domains refer to those binding domains with a Kaof at least 107M’1, at least 108M’1, at least 109M’1, at least IO10M’1, at least 1011M’1, at least 1012M’1, or at least 1013M’1. In particular embodiments, "low affinity" binding domains refer to those binding domains with a Kaof up to 107M’1, up to 106M’1, up to 105M’1. Alternatively, affinity may be defined as an equilibrium dissociation constant (Ka) of a particular binding interaction with units of M (e.g., 10'5M to 10'13M). In certain embodiments, a binding domain may have "enhanced affinity," which refers to a selected or engineered binding domains with stronger binding to a cognate binding molecule than a wild type (or parent) binding domain. For example, enhanced affinity may be due to a Ka(equilibrium association constant) for the cognate binding molecule that is higher than the reference binding domain or due to a Ka (dissociation constant) for the cognate binding20443-0963WO1 / INCY0626-WO1molecule that is less than that of the reference binding domain, or due to an off-rate (Koff) for the cognate binding molecule that is less than that of the reference binding domain. A variety of assays are known for detecting binding domains that specifically bind a particular cognate binding molecule as well as determining binding affinities, such as Western blot, ELISA, and BIACORE® analysis (see also, e.g., Scatchard, et al., 1949, Ann. N.Y. Acad. Sci. 57:660; and U.S. Patent Nos. 5,283,173, 5,468,614, or the equivalent).
[0174] Unless otherwise indicated, the practice of the present disclosure can employ conventional techniques of immunology, molecular biology, microbiology, cell biology and recombinant DNA. These methods are described in the following publications. See, e.g., Green and Sambrook, Molecular Cloning: A Laboratory Manual, 4th Edition (2012); F. M. Ausubel, et al. eds., Current Protocols in Molecular Biology, (2003); the series Methods In Enzymology (Academic Press, Inc.); Behlke, et al., Polymerase Chain Reaction: Theory and Technology (2019); Greenfield, ed. Antibodies, A Laboratory Manual, Second Edition (2014); and Capes-Davis and R. I. Freshney, eds. Freshney's Culture of Animal Cells 8th Edition (2021).
[0175] As will be understood by one of ordinary skill in the art, each embodiment disclosed herein can comprise, consist essentially of or consist of its particular stated element, step, ingredient or component. Thus, the terms “include” or “including” should be interpreted to recite: “comprise, consist of, or consist essentially of.” The transition term “comprise” or “comprises” means has, but is not limited to, and allows for the inclusion of unspecified elements, steps, ingredients, or components, even in major amounts. The transitional phrase “consisting of’ excludes any element, step, ingredient or component not specified. The transition phrase “consisting essentially of’ limits the scope of the embodiment to the specified elements, steps, ingredients or components and to those that do not materially affect the embodiment. A material effect would cause a statistically significant increase subjects not responding to cGVHD treatment, as described herein.
[0176] Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported20443-0963WO1 / INCY0626-WO1significant digits and by applying ordinary rounding techniques. When further clarity is required, the term “about” has the meaning reasonably ascribed to it by a person skilled in the art when used in conjunction with a stated numerical value or range, i.e. denoting somewhat more or somewhat less than the stated value or range, to within a range of ±20% of the stated value; ±19% of the stated value; ±18% of the stated value; ±17% of the stated value; ±16% of the stated value; ±15% of the stated value; ±14% of the stated value; ±13% of the stated value; ±12% of the stated value; ±11% of the stated value; ±10% of the stated value; ±9% of the stated value; ±8% of the stated value; ±7% of the stated value; ±6% of the stated value; ±5% of the stated value; ±4% of the stated value; ±3% of the stated value; ±2% of the stated value; or ±1% of the stated value.
[0177] Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the invention are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
[0178] The terms “a,” “an,” “the” and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
[0179] Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and / or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus20443-0963WO1 / INCY0626-WO1fulfilling the written description of all Markush groups used in the appended claims.
[0180] Certain embodiments of this invention are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
[0181] Furthermore, numerous references have been made to patents, printed publications, journal articles and other written text throughout this specification (referenced materials herein). Each of the referenced materials are individually incorporated herein by reference in their entirety for their referenced teaching.
[0182] In closing, it is to be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the present invention. Other modifications that may be employed are within the scope of the invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention may be utilized in accordance with the teachings herein. Accordingly, the present invention is not limited to that precisely as shown and described.
[0183] The particulars shown herein are by way of example and for purposes of illustrative discussion of the preferred embodiments of the present invention only and are presented in the cause of providing what is believed to be the most useful and readily understood description of the principles and conceptual aspects of various embodiments of the invention. In this regard, no attempt is made to show structural details of the invention in more detail than is necessary for the fundamental understanding of the invention, the description taken with the drawings and / or examples making apparent to those skilled in the art how the several forms of the invention may be embodied in practice.
[0184] Definitions and explanations used in the present disclosure are meant and intended to be controlling in any future construction unless clearly and unambiguously modified in the examples or when application of the meaning renders any construction meaningless or essentially meaningless. In cases where the construction of the term would render it meaningless or essentially meaningless, the definition should be taken from20443-0963WO1 / INCY0626-WO1Webster's Dictionary, 3rd Edition or a dictionary known to those of ordinary skill in the art, such as the Oxford Dictionary of Biochemistry and Molecular Biology (Eds. Attwood T et al., Oxford University Press, Oxford, 2006).
Claims
20443-0963WO1 / INCY0626-WO1What is claimed is:
1. A method of treating chronic GVHD (cGVHD) in a human subject in need thereof, comprising:determining that the human subject has cutaneous cGVHD that has not advanced to a sclerotic stage; andadministering a therapeutically effective amount of a CSF1R inhibitor to the human subject, thereby treating cGVHD in the human subject in need thereof.
2. The method of claim 1, wherein treating cGVHD comprises reducing occurrence of sclerotic cutaneous cGVHD.
3. The method of claim 1, wherein the determining comprises performing a physical examination.
4. The method of claim 1, wherein the determining comprises:obtaining a sample from the human subject,detecting one or more parameters of the sample and comparing the parameter(s) to a predetermined set of parameters derived from a reference sample; andbased on the comparing, administering the therapeutically effective amount of the CSF1R inhibitor to the human subject.
5. The method of claim 4, wherein the one or more parameters comprises one or more of:a proportion of macrophages expressing colony-stimulating factor 1 receptor (CSFlR)intand lysozyme (LYZ)hlin the sample;a distance between the CSFlRintLYZhlmacrophages and a basal keratinocyte (BK) layer in the sample;a proportion of CD8 T cells;a distance between CD8 T cells and CSFlRintLYZhlmacrophages and the BK layer; a distance between papillary fibroblasts and the BK layer;an expression level of IFNY, TBX21, and / or IL17A;an expression level of RORC;an expression level of GJB2, CD74, TGF 1, ZEB2, and / or KRT6B;20443-0963WO1 / INCY0626-WO1an expression level of CDH1 and / or CD9;an expression level of NOS2 and / or CD 163; andablation of a papillary fraction normally adjacent an epidermal-dermal border.
6. The method of claim 4 or claim 5, wherein detecting the one or more parameters comprises:detecting a proportion of macrophages expressing colony-stimulating factor 1 receptor CSFlRintLYZhlin the sample;detecting a distance between the CSFlRintLYZhlmacrophages and a BK layer in the sample; andcomparing the proportion and distance to a reference sample;wherein the determining that the human subject has cutaneous cGVHD that has not advanced to a sclerotic stage is by comparing the proportion and the distance with the parameters derived from the reference sample.
7. The method of claim 6, wherein CSFlRintLYZhlmacrophages are closer to the BK layer compared to information derived from the reference sample.
8. The method of claim 6, wherein the proportion of CSFlRintLYZhlmacrophages are increased compared to information derived from the reference sample and the CSFlRintLYZhlmacrophages are closer to the BK layer compared to information derived from the reference sample.
9. The method of claim 4 or claim 5, wherein detecting the one or more parameters comprises determining in the sample a proportion of CD8 T cells.
10. The method of claim 9, wherein the proportion of CD 8 T cells is increased compared to the parameters derived from the reference sample.
11. The method of claim 4 or claim 5, wherein detecting the one or more parameters comprises determining in the sample a distance between CD8 T cells and CSFlRintLYZhlmacrophages and the BK layer.20443-0963WO1 / INCY0626-WO112. The method of claim 11, wherein the distance between CD8 T cells and CSFlRintLYZhlmacrophages and the BK layer is decreased compared to theparameters derived from the reference sample.
13. The method of claim 4 or claim 5, wherein detecting the one or more parameters comprises determining in the sample a distance between papillary fibroblasts and the BK layer.
14. The method of claim 13, wherein the distance between papillary fibroblasts and the BK layer is decreased compared to the parameters derived from the reference sample.
15. The method of claim 4 or claim 5, wherein detecting the one or more parameters comprises determining in the sample an expression level of IFNY, TBX21, and / or IL 17 A.
16. The method of claim 15, wherein the expression level of IFNY is increased compared to the parameters derived from the reference sample.
17. The method of claim 15, wherein the expression level of TBX21 is increased compared to information derived from the reference sample.
18. The method of claim 15, wherein the expression level of IL17A is increased compared to the parameters derived from the reference sample.
19. The method of claim 4 or claim 5, wherein detecting the one or more parameters comprises determining in the sample an expression level of RORC.
20. The method of claim 19, wherein the expression level of RORC is increased compared to the parameters derived from the reference sample.
21. The method of claim 4 or claim 5, wherein detecting the one or more parameters comprises determining in the sample an expression level of GJB2, CD74, TGFpi, ZEB2, and / or KRT6B.20443-0963WO1 / INCY0626-WO122. The method of claim 21, wherein the expression level of GJB2 is increased compared to the parameters derived from the reference sample.
23. The method of claim 21, wherein the expression level of CD74 is increased compared to the parameters derived from the reference sample.
24. The method of claim 21, wherein the expression level of TGFpi is increased compared to the parameters derived from the reference sample.
25. The method of claim 21, wherein the expression level of ZEB2 is increased compared to the parameters derived from the reference sample.
26. The method of claim 21, wherein the expression level of KRT6B is increased compared to the parameters derived from the reference sample.
27. The method of claim 4 or claim 5, wherein detecting the one or more parameters comprises determining in the sample an expression level of CDH1 and / or CD9.
28. The method of claim 27, wherein the expression level of CDH1 is decreased compared to the parameters derived from the reference sample.
29. The method of claim 27, wherein the expression level of CD9 is decreased compared to the parameters derived from the reference sample.
30. The method of claim 4 or claim 5, wherein detecting the one or more parameters comprises determining in the sample an expression level of NOS2 and / or CD 163.
31. The method of claim 30, wherein the expression level of NOS2 is decreased compared to the parameters derived from the reference sample.
32. The method of claim 30, wherein the expression level of CD163 is increased compared to the parameters derived from the reference sample.
33. The method of claim 4 or claim 5, wherein detecting the one or more20443-0963WO1 / INCY0626-WO1parameters comprises determining in the sample an ablated cell type.
34. The method of claim 33, wherein the ablated cell type is a papillary fraction normally adjacent an epi dermal -dermal border compared to the parameters derived from the reference sample.
35. The method of claim 4, wherein the sample comprises a skin biopsy.
36. The method of claim 1, wherein the determining comprises single-cell RNA sequencing, flow cytometry, immunohistochemistry, immunofluorescence, mass spectrometry, nucleic acid sequencing, or spatial transcriptomics.
37. The method of claim 4, wherein the reference sample comprises a skin biopsy from a human subject that does not have cGVHD.
38. A method of treating chronic GVHD (cGVHD), comprising administering a therapeutically effective amount of a CSF1R inhibitor to a human subject previously identified as having cutaneous cGVHD that has not advanced to a sclerotic stage.
39. A method of treating chronic GVHD (cGVHD), comprising administering a therapeutically effective amount of a CSF1R inhibitor to a human subject having cutaneous cGVHD that has not advanced to a sclerotic stage.
40. The method of any one of claims 1 to 39, wherein the cutaneous cGVHD is in a lichenoid phase.
41. A method of treating cutaneous chronic graft versus host disease (cGVHD) in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of a CSF1R inhibitor, wherein the cGVHD is in a lichenoid phase prior to sclerosis and is characterized by an immune-infiltrated inflammatory pathology localized to the epidermal-dermal interface, and wherein the human subject exhibits: (i) a macrophage population expressing intermediate levels of CSF1R and high levels of lysozyme; and (ii) localization of said macrophages at or in direct proximity to the basal keratinocyte layer.20443-0963WO1 / INCY0626-WO142. A method of treating cutaneous chronic graft versus host disease (cGVHD) in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of a CSF1R inhibitor, wherein the cGVHD is in a lichenoid phase prior to sclerosis, and wherein the human subject exhibits one or more of the following biological features in a skin sample compared to a reference skin sample:an increased proportion of macrophages expressing colony-stimulating factor 1 receptor (CSFlR)intand lysozyme (LYZ)hlin the sample;a reduced distance between the CSFlRintLYZhlmacrophages and a basal keratinocyte (BK) layer in the sample;an increased proportion of CD8 T cells;a reduced distance between CD8 T cells and CSFlRintLYZhlmacrophages and the BK layer;a reduced distance between papillary fibroblasts and the BK layer;an increased expression level of IFNY, TBX21, and / or IL17A;an increased expression level of RORC;an increased expression level of GJB2, CD74, TGFpi, ZEB2, and / or KRT6B;a decreased expression level of CDH1 and / or CD9;a decreased expression level of NOS2 and / or increased expression level of CD163; anda partial or complete ablation of a papillary fraction normally adjacent an epidermal- dermal border.
43. The method of claim 42, wherein the reference sample comprises a skin biopsy from a human subject that does not have cGVHD.
44. The method of any one of claims 1 to 43, wherein the human subject has skin lesions.
45. The method of claim 44, wherein the skin lesions comprise papules, plaques, or fine scales.
46. The method of claim 44, wherein the skin lesions are erythematous or violaceous.20443-0963WO1 / INCY0626-WO147. The method of claim 44, wherein the skin lesions are on a hand, forearm, or trunk of the human subject.
48. The method of any one of claims 1 to 47, wherein the CSF1R inhibitor comprises axatilimab.
49. The method of any one of claims 1 to 48, wherein the therapeutically effective amount comprises 0.1-5 mg / kg of the CSF1R inhibitor every 1 to 6 weeks.
50. The method of any one of claims 1 to 48, wherein the therapeutically effective amount comprises 0.3-3 mg / kg of the CSF1R inhibitor every 2 to 4 weeks.
51. The method of any one of claims 1 to 48, wherein the therapeutically effective amount comprises 0.3 mg / kg of the CSF1R inhibitor every 2 weeks.
52. The method of any one of claims 1 to 48, wherein the therapeutically effective amount comprises 1 mg / kg of the CSF1R inhibitor every 2 weeks.
53. The method of any one of claims 1 to 48, wherein the therapeutically effective amount comprises 3 mg / kg of the CSF1R inhibitor every 4 weeks.
54. The method of any one of claims 1 to 53, wherein the therapeutically effective amount comprises six doses of CSF1R inhibitor.
55. The method of any one of claims 1 to 54, wherein the human subject received an allogeneic hematopoietic cell transplantation (HCT).
56. The method of any one of claims 1 to 54, wherein the human subject received an allogeneic HCT within the past 200 days.
57. The method of any one of claims 1 to 54, wherein the human subject received an allogeneic HCT within the past 100 days.
58. The method of any one of claims 1 to 54, wherein the administering occurs20443-0963WO1 / INCY0626-WO1within 1 year of receiving an allogeneic HCT.
59. The method of any one of claims 1 to 54, wherein the administering occurs within 30 weeks of receiving an allogeneic HCT.
60. The method of any one of claims 1 to 54, wherein the administering occurs within 24 weeks of receiving an allogeneic HCT.
61. The method of any one of claims 1 to 54, wherein the administering occurs after 100 days of receiving an allogeneic HCT.
62. The method of any one of claims 1 to 61, wherein the administering occurs for up to 2 years.
63. The method of any one of claims 1 to 62, wherein the administering comprises intravenous, intradermal, intraarterial, parenteral, intranasal, intralesional, intramuscular, oral, subcutaneous, or sublingual administration.
64. The method of any one of claims 1 to 62, wherein the administering comprises intravenous administration.
65. A method of treating a human subject in need thereof comprising:obtaining a sample from the human subject;detecting a proportion of macrophages expressing colony-stimulating factor 1 receptor (CSFlR)intand lysozyme (LYZ)hlin the sample;determining a distance between the CSFlRintLYZhlmacrophages and a basal keratinocyte (BK) layer in the sample;comparing the proportion and distance to information derived from a reference sample; andbased on the comparing, administering a therapeutically effective amount of a CSF1R inhibitor to the human subject,thereby treating the human subject in need thereof.
66. The method of claim 65, wherein the human subject has cutaneous chronic20443-0963WO1 / INCY0626-WO1graft-versus-host disease (cGVHD).
67. The method of claim 66, wherein the cutaneous cGVHD is in a lichenoid phase.
68. The method of claim 65, wherein the human subject has skin lesions.
69. The method of claim 68, wherein the skin lesions comprise papules, plaques, or fine scales.
70. The method of claim 68, wherein the skin lesions are erythematous or violaceous.
71. The method of claim 68, wherein the skin lesions are on a hand, forearm, or trunk of the human subject.
72. The method of claim 66, wherein the cutaneous cGVHD has not progressed to a sclerotic phase.
73. The method of claim 65, wherein the distance is a relative distance as compared to a different cell type.
74. The method of claim 65, wherein the human subject received an allogeneic hematopoietic cell transplantation (HCT).
75. The method of claim 65, wherein the human subject received an allogeneic HCT within the past 200 days.
76. The method of claim 65, wherein the human subject received an allogeneic HCT within the past 100 days.
77. The method of claim 65, wherein the sample comprises a skin biopsy.
78. The method of claim 65, wherein the detecting comprises single-cell RNA20443-0963WO1 / INCY0626-WO1sequencing, flow cytometry, immunohistochemistry, immunofluorescence, mass spectrometry, nucleic acid sequencing, or spatial transcriptomics.
79. The method of claim 65, wherein the determining the distance comprises immunofluorescence, immunohistochemistry, or spatial transcriptomics.
80. The method of claim 65, wherein the reference sample comprises a skin biopsy from a human subject that does not have cGVHD.
81. The method of claim 65, wherein the proportion of CSFlRintLYZhlmacrophages are increased compared to information derived from the reference sample.
82. The method of claim 65, wherein CSFlRintLYZhlmacrophages are closer to the basal keratinocyte layer compared to information derived from the reference sample.
83. The method of claim 65, wherein the proportion of CSFlRintLYZhlmacrophages are increased compared to information derived from the reference sample and the CSFlRintLYZhlmacrophages are closer to the basal keratinocyte layer compared to information derived from the reference sample.
84. The method of claim 65, wherein the method further comprises determining in the sample a proportion of CD8 T cells.
85. The method of claim 84, wherein the proportion of CD 8 T cells is increased compared to the information derived from the reference sample.
86. The method of claim 65, wherein the method further comprises determining in the sample a distance between CD8 T cells and CSFlRintLYZhlmacrophages and the BK layer.
87. The method of claim 86, wherein the distance between CD8 T cells and CSFlRintLYZhlmacrophages and the BK layer is decreased compared to information derived from the reference sample.20443-0963WO1 / INCY0626-WO188. The method of claim 65, wherein the method further comprises determining in the sample a distance between papillary fibroblasts and the BK layer.
89. The method of claim 88, wherein the distance between papillary fibroblasts and the BK layer is decreased compared to information derived from the reference sample.
90. The method of claim 65, wherein the method further comprises determining in the sample an expression level of IFNY, TBX21, and / or IL17A.
91. The method of claim 90, wherein the expression level of IFNY is increased compared to information derived from the reference sample.
92. The method of claim 90, wherein the expression level of TBX21 is increased compared to information derived from the reference sample.
93. The method of claim 90, wherein the expression level of IL17A is increased compared to information derived from the reference sample.
94. The method of claim 65, wherein the method further comprises determining in the sample an expression level of RORC.
95. The method of claim 94, wherein the expression level of RORC is increased compared to information derived from the reference sample.
96. The method of claim 65, wherein the method further comprises determining in the sample an expression level of GJB2, CD74, TGFpi, ZEB2, and / or KRT6B.
97. The method of claim 96, wherein the expression level of GJB2 is increased compared to information derived from the reference sample.
98. The method of claim 96, wherein the expression level of CD74 is increased compared to information derived from the reference sample.
99. The method of claim 96, wherein the expression level of TGFpi is increased20443-0963WO1 / INCY0626-WO1compared to information derived from the reference sample.
100. The method of claim 96, wherein the expression level of ZEB2 is increased compared to information derived from the reference sample.
101. The method of claim 96, wherein the expression level of KRT6B is increased compared to information derived from the reference sample.
102. The method of claim 96, wherein the method further comprises determining in the sample an expression level of CDH1 and / or CD9.
103. The method of claim 102, wherein the expression level of CDH1 is decreased compared to information derived from the reference sample.
104. The method of claim 102, wherein the expression level of CD9 is decreased compared to information derived from the reference sample.
105. The method of claim 65, wherein the method further comprises determining in the sample an expression level of NOS2 and / or CD 163.
106. The method of claim 105, wherein the expression level of NOS2 is decreased compared to information derived from the reference sample.
107. The method of claim 105, wherein the expression level of CD163 is increased compared to information derived from the reference sample.
108. The method of claim 65, wherein the method further comprises determining in the sample an ablated cell type.
109. The method of claim 108, wherein the ablated cell type is a papillary fraction normally adjacent an epidermal-dermal border compared to information derived from the reference sample.
110. The method of claim 65, wherein the CSF1R inhibitor comprises axatilimab.20443-0963WO1 / INCY0626-WO1111. The method of claim 65, wherein the therapeutically effective amount comprises 0.1-5 mg / kg of the CSF1R inhibitor every 1 to 6 weeks.
112. The method of claim 65, wherein the therapeutically effective amount comprises 0.3-3 mg / kg of the CSF1R inhibitor every 2 to 4 weeks.
113. The method of claim 65, wherein the therapeutically effective amount comprises 0.3 mg / kg of the CSF1R inhibitor every 2 weeks.
114. The method of claim 65, wherein the therapeutically effective amount comprises 1 mg / kg of the CSF1R inhibitor every 2 weeks.
115. The method of claim 65, wherein the therapeutically effective amount comprises 3 mg / kg of the CSF1R inhibitor every 4 weeks.
116. The method of claim 65, wherein the therapeutically effective amount comprises six doses of CSF1R inhibitor.
117. The method of claim 65, wherein the administering occurs within 1 year of receiving an allogeneic HCT.
118. The method of claim 65, wherein the administering occurs within 30 weeks of receiving an allogeneic HCT.
119. The method of claim 65, wherein the administering occurs within 24 weeks of receiving an allogeneic HCT.
120. The method of claim 65, wherein the administering occurs after 100 days of receiving an allogeneic HCT.
121. The method of claim 65, wherein the administering occurs for up to 2 years.
122. The method of claim 65, wherein the administering comprises intravenous, intradermal, intraarterial, parenteral, intranasal, intralesional, intramuscular, oral,20443-0963WO1 / INCY0626-WO1subcutaneous, or sublingual administration.
123. The method of claim 65, wherein the administering comprises intravenous administration.
124. A method of predicting that a human subject having cutaneous graft-versus-host disease (cGVHD) will respond to a colony-stimulating factor 1 receptor (CSF1R) inhibitor comprising:measuring biomarker expression of fibroblasts;comparing the biomarker expression to a corresponding reference level; and determining the human subject will respond to the CSF1R inhibitor.
125. The method of claim 124, wherein the cGVHD is in an early lichenoid phase.
126. The method of claim 124, wherein the CSF1R inhibitor comprises axatilimab.
127. The method of claim 124, wherein the biomarker is a nucleic acid.
128. The method of claim 124, wherein the measuring comprises obtaining a skin biopsy from the human subject and quantifying biomarker expression of fibroblasts from the skin biopsy.
129. The method of claim 124, wherein the measuring biomarker expression comprises performing spatial transcriptomics sequencing, bulk RNA sequencing, single-cell RNA sequencing, chromatin accessibility sequencing, DNA-associated proteins sequencing, or multiplexed RNA fluorescence in situ hybridization (FISH).
130. The method of claim 124, wherein the measuring biomarker expression comprises performing spatial transcriptomics.
131. The method of claim 124, wherein the reference level is derived from a nonresponder.
132. The method of claim 131, wherein the fibroblasts comprise LGR5+ fibroblasts and the expression level of collagen genes, SPARC, and / or SFRP2 are decreased compared to20443-0963WO1 / INCY0626-WO1the reference level.
133. The method of claim 131, wherein the fibroblasts comprise papillary fibroblasts and the expression level of POSTN is decreased compared to the reference level.
134. The method of claim 131, wherein the fibroblasts comprise papillary fibroblasts and the expression level of ADH1B is increased compared to the reference level.
135. The method of claim 124, wherein the reference level is derived from a responder.
136. The method of claim 135, wherein the fibroblasts comprise LGR5+ fibroblasts and the expression level of collagen genes, SPARC, and / or SFRP2 are significantly similar compared to the reference level.
137. The method of claim 136, wherein the fibroblasts comprise papillary fibroblasts and the expression level of POSTN is significantly similar compared to the reference level.
138. The method of claim 136, wherein the fibroblasts comprise papillary fibroblasts and the expression level of ADH1B is significantly similar compared to the reference level.
139. A method of treating a human subject having cutaneous graft-versus-host disease (cGVHD), comprising:predicting that the human subject will respond to a colony-stimulating factor 1 receptor (CSF1R) inhibitor according to the method of any one of claims 124 to 138; andadministering a therapeutically effective amount of the CSF1R inhibitor to the human subject.
140. The method of claim 139, further comprising measuring biomarker expression of fibroblasts after the administering.20443-0963WO1 / INCY0626-WO1141. The method of claim 139, wherein the administering comprises intravenous, intradermal, intraarterial, parenteral, intranasal, intralesional, intramuscular, oral, subcutaneous, or sublingual administration.
142. The method of claim 139, wherein the administering comprises intravenous administration.
143. The method of claim 139, wherein the therapeutically effective amount comprises 0.1-5 mg / kg of the CSF1R inhibitor every 1 to 6 weeks.
144. The method of claim 139, wherein the therapeutically effective amount comprises 0.3-3 mg / kg of the CSF1R inhibitor every 2 to 4 weeks.
145. The method of claim 139, wherein the therapeutically effective amount comprises 0.3 mg / kg of the CSF1R inhibitor every 2 weeks.
146. The method of claim 139, wherein the therapeutically effective amount comprises 1 mg / kg of the CSF1R inhibitor every 2 weeks.
147. The method of claim 139, wherein the therapeutically effective amount comprises 3 mg / kg of the CSF1R inhibitor every 4 weeks.
148. The method of claim 139, wherein the therapeutically effective amount comprises six doses of CSF1R inhibitor.
149. The method of claim 139, wherein the administering occurs within 30 weeks.
150. The method of claim 139, wherein the administering occurs within 24 weeks.
151. The method of claim 139, wherein the reference level is derived from a nonresponder.
152. The method of claim 151, wherein the expression level of IGFBP7 and / or CCND1 is decreased compared to the reference level.20443-0963WO1 / INCY0626-WO1153. The method of claim 151, wherein the expression level of LGR5 is increased compared to the reference level.
154. The method of claim 151, wherein the expression level of ACTA2, COL5A2, and / or SPON2 is decreased compared to the reference level.
155. The method of claim 124, wherein the reference level is derived from a responder.
156. The method of claim 155, wherein the expression level of IGFBP7 and / or CCND1 is increased compared to the reference level.
157. The method of claim 155, wherein the expression level of LGR5 is decreased compared to the reference level.
158. The method of claim 155, wherein the expression level of ACTA2, COL5A2, and / or SPON2 is increased compared to the reference level.
159. The method of claim 124, wherein the human subject received a hematopoietic cell transplantation (HCT).
160. A method of treating a human subject with cutaneous lichenoid phase chronic graft versus host disease (cGVHD) before sclerosis occurs, the method comprising:obtaining a sample from the human subject;determining a parameter comprising one or more of:a proportion of macrophages expressing colony-stimulating factor 1 receptor (CSFlR)intand lysozyme (LYZ)hlin the sample;a distance between the CSFlRintLYZhlmacrophages and a basal keratinocyte (BK) layer in the sample;a proportion of CD8 T cells;a distance between CD8 T cells and CSFlRintLYZhlmacrophages and the BK layer;a distance between papillary fibroblasts and the BK layer;an expression level of IFNY, TBX21, and / or IL17A;20443-0963WO1 / INCY0626-WO1an expression level of RORC;an expression level of GJB2, CD74, TGF 1, ZEB2, and / or KRT6B;an expression level of CDH1 and / or CD9;an expression level of NOS2 and / or CD 163; andablation of a papillary fraction normally adjacent an epidermal-dermal border; comparing the parameter to information derived from a reference sample; and based on the comparing, administering a therapeutically effective amount of a CSF1R inhibitor to the human subject,thereby treating the human subject with cutaneous lichenoid phase chronic graft versus host disease (cGVHD) before sclerosis occurs.
161. A CSF1R inhibitor for use in the treatment of cutaneous chronic graft versus host disease (cGVHD) in a human subject, wherein the cGVHD is in a lichenoid phase prior to sclerosis and is characterized by an immune-infiltrated inflammatory pathology localized to the epidermal-dermal interface, and wherein the human subject exhibits: (i) a macrophage population expressing intermediate levels of CSF1R and high levels of lysozyme; and (ii) localization of said macrophages at or in direct proximity to the basal keratinocyte layer.
162. A CSF1R inhibitor for use in the treatment of cutaneous chronic graft versus host disease (cGVHD) in a human subject, wherein the cGVHD is in a lichenoid phase prior to sclerosis, and wherein the human subject exhibits one or more of the following biological features in a skin sample compared to a reference skin sample:an increased proportion of macrophages expressing colony-stimulating factor 1 receptor (CSFlR)intand lysozyme (LYZ)hlin the sample;a reduced distance between the CSFlRintLYZhlmacrophages and a basal keratinocyte (BK) layer in the sample;an increased proportion of CD8 T cells;a reduced distance between CD8 T cells and CSFlRintLYZhlmacrophages and the BK layer;a reduced distance between papillary fibroblasts and the BK layer;an increased expression level of IFNY, TBX21, and / or IL17A;an increased expression level of RORC;an increased expression level of GJB2, CD74, TGFpi, ZEB2, and / or KRT6B;20443-0963WO1 / INCY0626-WO1a decreased expression level of CDH1 and / or CD9;a decreased expression level of NOS2 and / or increased expression level of CD163; anda partial or complete ablation of a papillary fraction normally adjacent an epidermal- dermal border.
163. The CSF1R inhibitor for use of claim 161 or 162, wherein the CSF1R inhibitor comprises axatilimab.
